



0 / - 31 . 00

17

DOCKET NO. : UPN-3832

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

Mark I. Greene, Ramachandran Murali,  
Kazuhiro Aoki, William Carle Horne and  
Roland Baron

**Serial No.:** Not yet assigned

**Group Art Unit:** Not yet assigned

**Filing Date:** Herewith

**Examiner:** Not yet assigned

**For:** METHODS OF INHIBITING OSTEOCLASTOGENESIS

**EXPRESS MAIL LABEL NO:** EL531276548US  
**DATE OF DEPOSIT:** July 28, 2000

Box ☒ Patent Application  
☐ Provisional ☐ Design

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

**PATENT APPLICATION TRANSMITTAL LETTER**

Transmitted herewith for filing, please find

☒ A Utility Patent Application under 37 C.F.R. 1.53(b).

It is a continuing application, as follows:

☐ continuation ☐ divisional ☐ continuation-in-part of prior application number  
\_\_\_\_/\_\_\_\_.

☐ A Provisional Patent Application under 37 C.F.R. 1.53(c).

☐ A Design Patent Application (submitted in duplicate).

Including the following:

09/627775 "07/28/00"

☐ Provisional Application Cover Sheet.

☒ New or Revised Specification, including pages 1 to 63 containing:

☒ Specification

☒ Claims

☒ Abstract

☐ Substitute Specification, including Claims and Abstract.

☐ The present application is a continuation application of Application No. \_\_\_\_\_ filed \_\_\_\_\_. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.

☐ The present application is a continuation application of Application No. \_\_\_\_\_ filed \_\_\_\_\_, which in turn is a continuation-in-part of Application No. \_\_\_\_\_ filed \_\_\_\_\_. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.

☐ A copy of earlier application Serial No. \_\_\_\_\_ Filed \_\_\_\_\_, including Specification, Claims and Abstract (pages 1 - @@), to which no new matter has been added TOGETHER WITH a copy of the executed oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.

☐ Please enter the following amendment to the Specification under the Cross-Reference to Related Applications section (or create such a section) : "This Application:

☐ is a continuation of ☐ is a divisional of ☐ claims benefit of U.S. provisional Application Serial No. \_\_\_\_\_ filed \_\_\_\_\_

---

- 
- 
- 
- ☐ Signed Statement attached deleting inventor(s) named in the prior application.
- ☐ A Preliminary Amendment.
- ☒ 1 Sheet of a ☒ Formal ☐ Informal Drawing.
- ☐ Petition to Accept Photographic Drawings.
- ☐ Petition Fee
- ☒ An ☐ Executed ☒ Unexecuted Declaration or Oath and Power of Attorney.
- ☐ An Associate Power of Attorney.
- ☐ An ☐ Executed ☐ Copy of Executed Assignment of the Invention to \_\_\_\_\_
- ☐ A Recordation Form Cover Sheet.
- ☐ Recordation Fee - \$40.00.
- ☐ The prior application is assigned of record to \_\_\_\_\_
- ☐ Priority is claimed under 35 U.S.C. § 119 of Patent Application No. \_\_\_\_\_  
filed \_\_\_\_\_ in \_\_\_\_\_ (country).
- ☐ A Certified Copy of each of the above applications for which priority is claimed:
- ☐ is enclosed.
- ☐ has been filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_.
- ☐ An ☐ Executed or ☐ Copy of Executed Earlier Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27
- ☐ is enclosed.
- ☐ has been filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_, said status is still proper and desired in present case.

- ☒ Diskette Containing DNA/Amino Acid Sequence Information.
- ☒ Statement to Support Submission of DNA/Amino Acid Sequence Information.
- ☐ The computer readable form in this application \_\_\_\_\_, is identical with that filed in Application Serial Number \_\_\_\_\_, filed \_\_\_\_\_. In accordance with 37 CFR 1.821(e), please use the ☐ first-filed, ☐ last-filed or ☐ only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is ☐ included in the originally-filed specification of the instant application, ☐ included in a separately filed preliminary amendment for incorporation into the specification.
- ☐ Information Disclosure Statement.
- ☐ Attached Form 1449.
- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ A copy of Petition for Extension of Time as filed in the prior case.
- ☐ Appended Material as follows: \_\_\_\_\_
- ☒ Return Receipt Postcard (should be specifically itemized).
- ☐ Other as follows: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_.

**FEE CALCULATION:**

- ☐ Cancel in this application original claims \_\_\_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

				SMALL ENTITY		NOT SMALL ENTITY	
				RATE	FEE	RATE	FEE
PROVISIONAL APPLICATION				\$75.00	\$	\$150.00	\$
DESIGN APPLICATION				\$155.00	\$	\$310.00	\$
UTILITY APPLICATIONS BASE FEE				\$345.00	\$345.00	\$690.00	\$
UTILITY APPLICATION; ALL CLAIMS CALCULATED AFTER ENTRY OF ALL AMENDMENTS							
		No. Filed	No. Extra				
TOTAL CLAIMS	48- 20 =	28		\$9 each	\$252.00	\$18 each	\$
INDEP. CLAIMS	3- 3 =	0		\$39 each	\$0	\$78 each	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM				\$130	\$	\$260	\$
ADDITIONAL FILING FEE					\$		\$
TOTAL FILING FEE DUE					\$597.00		\$

- ☒ A Check is enclosed in the amount of \$ 597.00.
- ☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- ☐ The foregoing amount due.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).
- ☐ The issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance.
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-



## **METHODS OF INHIBITING OSTEOCLASTOGENESIS**

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application U.S. Application Serial No. 60/146,090, filed July 28, 1999, which is hereby incorporated by reference in its entirety.

### **5 ACKNOWLEDGMENT OF GOVERNMENT RIGHTS**

The present invention was made under Grant EY09332 from the National Institutes of Health. The Government may have certain rights to the invention.

### **FIELD OF THE INVENTION**

The present invention relates to the methods of down-modulating  
10 osteoclastogenesis activity, thereby inhibiting bone matrix erosion and thus preventing  
bone loss and treating bone diseases. The present invention also relates to peptides and  
peptide analogues which inhibit TNF binding to its cellular receptors, methods of  
designing similar peptides and peptide analogues, and methods of using such compounds  
to inhibit the biological activities of TNF particularly those activities relating to bone  
15 resorption, thereby antagonizing its undesirable clinical effects.

### **BACKGROUND OF THE INVENTION**

Osteoclasts are large multinuclear cells which function to erode bone matrix. They are related to macrophage and other cells that develop from monocyte cells. Like macrophage, osteoclasts are derived from haematopoietic progenitor cells.

Bone matrix erosion is a normal process which occurs in coordination with  
5 bone matrix formation, a process in which osteoblasts are involved. Essentially, osteoblasts erode bone matrix and tunnel into bone while osteoblasts follow, line the walls of the tunnel and form new bone matrix. Typically, in a normal adult, about 5-10% of bone is replaced by these processes annually.

Bone diseases such as osteoporosis and Paget's disease are characterized by  
10 a loss of bone. Similarly, metastatic bone disease, rheumatoid arthritis, and periodontal bone disease are also characterized by bone loss. In many cases, bone loss leads to fractures in patients. In addition to pain and suffering, patients become physically impaired which often leads to complications having negative consequences on patient health and quality of life. Moreover, the economic costs attributable to these diseases are  
15 tremendous.

Receptors and ligands of the Tumor Necrosis Factor (TNF) family have recently been shown to play an essential part in the differentiation and activity of osteoclasts and therefore play a role in bone resorption. On the one hand, TNF- $\alpha$  is known to promote osteoclastogenesis, the generation of osteoclasts. On the other hand, a TNF-  
20 like molecule present on and/or secreted by osteoclasts and stromal cells, referred to interchangeably in the field and herein as "Receptor activator of NF- $\kappa$ B ligand", (RANKL), "Osteoclast differentiation factor" (ODF), "Osteoprotegerin ligand" (OPGL), and "TNF-related activation-induced cytokine" (TRANCE), interacts with a TNF-receptor-like molecule, referred to in the field and herein as "Receptor activator of NF- $\kappa$ B ligand",  
25 (RANK), which, present in the membranes of osteoclast precursors and mature osteoclasts, regulates osteoclastogenesis and the resorbing activity of mature osteoclasts. The utilization of TNF- $\alpha$  antagonists, such as a monoclonal antibodies, for therapeutic purposes, has proven difficult, however, because of immunity to the large molecule, and limited entry into some specialized compartments of the body. Suda, *et al.* (Endocrine  
30 Reviews 20(3):345-357, 1999), which is incorporated herein by reference, describe osteoclast differentiation and function. Filvaroff, E and R. Derynck (Curr. Biol. 8:R679-



R682, 1998) which is incorporated herein by reference, refer to bone remodeling and a signaling system for osteoclast regulation.

Thus, there is a need for methods of regulating osteoclastogenesis and the resorbing activity of mature osteoclasts. There is also a need for methods of preventing  
5 bone loss and treating bone diseases.

## SUMMARY OF THE INVENTION

The present invention relates to methods of inhibiting osteoclastogenesis and the resorbing activity of mature osteoclasts. According to the present invention, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclast bone erosion activity  
10 is administered to a patient.

The present invention relates to methods of treating patients who have diseases characterized by bone loss. According to the present invention, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to a patient.

15 The present invention relates to pharmaceutical compositions which comprise a TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis.

The present invention relates to methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual comprising the step of administering to the individual an amount of a TRANCE/RANK inhibitor  
20 effective to modulate dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.


The present invention relates to the use of peptides and peptide analogues designed from a binding loop of a TNF-R superfamily member. In particular, it relates to the use of peptides and peptide analogues designed from three binding loops of TNF-R.  
25 More specifically, the invention relates to peptides and peptide analogues which inhibit activities relating to bone resorption.

Generally, compounds used in the present invention are cyclic peptides or peptide analogues which are modified at their termini with hydrophobic moieties. In embodiments wherein the compound is a peptide, the peptide corresponds in primary  
30 sequence to a binding loop of a member of the TNF-R superfamily or a portion thereof. In

a preferred embodiment, the peptide used in the invention corresponds in primary sequence to a binding loop of TNF-R p55 or a portion thereof. In certain embodiments, one or more amino acid residues within the peptide are substituted with other amino acid residues. Typically, such amino acid substitutions are conservative, *i.e.*, the amino acid

- 5 residues are replaced with other amino acid residues having similar physical and/or chemical properties. In embodiments wherein the compound is a peptide analogues, the analogues is obtained by replacing at least one amide linkage in the peptide with a substituted amide or an isostere of amide.

- 10 In an illustrative embodiment, a compound used in the invention has the following formula:



(I)

wherein:

- AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally  
15 contain one or more conservative amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

- AB<sub>1</sub> is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>2</sub> and a third functional group capable of forming a covalent  
20 linkage with AA<sub>1</sub>;

AB<sub>2</sub> is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>1</sub> and a third functional group capable of forming a covalent linkage with AA<sub>2</sub>;

AA<sub>1</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>1</sub>;

AA<sub>2</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>;

- 5           “=” is a covalent linkage; and  
          “≡” is a covalent linkage.

In a preferred embodiment of the compounds of formula (I), AC is a peptide which corresponds in primary sequence to a binding loop of TNF-R p55 and which optionally may contain one or more conservative amino acid substitutions, or an analogue  
10 thereof. In a particularly preferred embodiment, the peptides and peptide analogues specifically inhibit osteoclastogenesis.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the sequence alignment of amino acids in certain extracellular Cys-rich domains of TNF-R superfamily members: TNF-R p55 (SEQ ID  
15 NO:1), TNF-R p 75 (SEQ ID NO:2), TNF-R-rp (SEQ ID NO: 3), NGF-R p75 (SEQ ID NO: 4), CD27 (SEQ ID NO:5), CD30 (proximal) SEQ ID NO:6), CD30 (distal) (SEQ ID NO:7), CD40 (SEQ ID NO:10), and 4-IBB (SEQ ID NO:11).

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The invention provides methods for treating individuals that have diseases  
20 characterized by bone loss. TRANCE/RANK inhibitors are administered to the individual in an amount effective to inhibit osteoclastogenesis and/or osteoclast function and thereby reduce bone loss, *i.e.* a therapeutically effective amount.

The invention also provides novel therapeutic pharmaceutical compositions for treating diseases characterized by bone loss. The pharmaceutical compositions  
25 comprise a therapeutically effective amount of TRANCE/RANK inhibitors and a pharmaceutically acceptable carrier or diluent. In preferred embodiments, the pharmaceutical compositions are injectable pharmaceutical compositions, *i.e.* they are

sterile, pyrogen-free, free of particulate matter, essentially isotonic, and are otherwise suitable for injection into humans.

As used herein, the term "TRANCE/RANK inhibitors" refers to peptides and peptide analogues which inhibit osteoclastogenesis and/or osteoclast function.

- 5 TRANCE/RANK inhibitors can function as an antagonist of the cellular receptor RANK by inhibiting TRANCE/RANK.

- As used herein, the term "diseases characterized by bone loss" is meant to refer to diseases, conditions, disorders and syndromes which have as a symptom or pathology a decrease in bone mass or density. Examples of diseases characterized by bone
- 10 loss include, but are not limited to, osteoporosis, Paget's disease, metastatic bone disease, rheumatoid arthritis and periodontal bone disease.

As used herein, the term "bone resorption" refers to the undesired loss of bone caused at least in part by osteoclast activity.

- As used herein, the term "therapeutically effective amount" is meant to refer
- 15 to an amount of a compound which produces a medicinal effect observed as reduction in the rate of bone loss in an individual when a therapeutically effective amount of a compound is administered to an individual who is susceptible to or suffering from a disease characterized by bone loss. Therapeutically effective amounts are typically determined by the effect they have compared to the effect observed when a composition
- 20 which includes no active ingredient (*i.e.* a control) is administered to a similarly situated individual.

- As used herein, the term "inhibit" means to decrease the amount, quality, or effect of a particular activity and is used interchangeably with the terms "reduce", "minimize", and "lessen" and refers to, for example, the reduction of osteoclast bone
- 25 erosion activity caused by the administration of a therapeutically effective amount of the compounds of the present invention to a patient.

- As used herein, the term "alkyl" refers to a saturated branched, straight chain or cyclic hydrocarbon group. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, and the like. In
- 30 preferred embodiments, the alkyl groups are (C<sub>1</sub>-C<sub>5</sub>) alkyl, with (C<sub>1</sub>-C<sub>3</sub>) being particularly preferred.

As used herein, the term “substituted alkyl” refers to an alkyl group wherein one or more hydrogen atoms are each independently replaced with other substituents.

As used herein, the term “alkenyl” refers to an unsaturated branched, straight chain or cyclic hydrocarbon group having at least one carbon-carbon double bond. The group  
5 may be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, tert-butenyl, pentenyl, hexenyl and the like. In preferred embodiments, the alkenyl group is (C<sub>1</sub>-C<sub>6</sub>) alkenyl, with (C<sub>1</sub>-C<sub>3</sub>) being particularly preferred.

As used herein, the term “alkynyl” refers to an unsaturated branched, straight chain  
10 or cyclic hydrocarbon group having at least one carbon-carbon triple bond. Typical alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, isobutynyl, pentynyl, hexynyl and the like. In preferred embodiments, the alkynyl group is (C<sub>1</sub>-C<sub>6</sub>) alkynyl, with (C<sub>1</sub>-C<sub>3</sub>) being particularly preferred.

As used herein, the term “substituted alkynyl” refers to an alkynyl group wherein  
15 one or more hydrogen atoms are each independently replaced with other substituents.

As used herein, the term “alkoxy” refers to an -OR group, where R is alkyl, alenyl or alkynyl, as defined above.

As used herein, the term “aromatic moiety” refers to a moiety having an unsaturated cyclic hydrocarbon group which has a conjugated (4n+2)  $\pi$  electron system.  
20 typical aromatic moieties include, but are not limited to, benzene, naphthalene, anthracene, azulene, indacene, and the like. In preferred embodiments, the aromatic moiety contains 5-20 carbons in the ring system, with 5-10 carbon atoms being particularly preferred.

As used herein, the term “substituted aromatic moiety” refers to an aromatic moiety wherein one or more hydrogen atoms are each independently replaced with other  
25 substituents.

As used herein, the term “heteroaromatic moiety” refers to an aromatic moiety wherein one or more of the ring carbon atoms is replaced with another atom such as N, O or S. Typical heteroaromatic moieties include, but are not limited to, pyran, pyrazole, pyridine, pyrrolke, pyrazine, pyridazine, pyrimidine, pyrrolizine, quinazoline, quinoline,  
30 quinolizine, quinoxaline, selenophene, thiophere, tellurophene, xanthene and the like.

As used herein, the term “substituted heteroaromatic moiety” refers to a

heteroaromatic moiety wherein one or more hydrogen atoms are each independently replaced with other substituents.

Applicants have discovered that the peptides described *infra* are useful to inhibit osteoclastogenesis and/or osteoclast function. By inhibiting osteoclastogenesis and/or  
5 osteoclast function, bone erosion can be minimized or even prevented, and bone loss can be reduced. Patients suffering from diseases characterized by bone loss can be treated by administering an amount of compound effective to inhibit osteoclastogenesis and/or osteoclast function. In addition, patients identified as being susceptible to diseases characterized by bone loss can be prophylactically treated by administering an amount of  
10 compound effective to inhibit osteoclastogenesis and/or osteoclast function.

Individuals who have a disease characterized by bone loss can be identified by those having ordinary skill in the art by well known diagnostic means and criteria. Individuals who are susceptible to a disease characterized by bone loss can be identified by those having ordinary skill in the art based upon family medical history and/or the presence  
15 of genetic markers or genes associated with a disease characterized by bone loss.

According to the invention, TRANCE/RANK inhibitors useful in the invention are compounds described *infra* such as peptides and peptide analogues designed from a binding loop of a TNF-R superfamily member which function to inhibit osteoclastogenesis and/or osteoclast function. Such compounds may be produced by the methods described  
20 *infra* or by other techniques well known to those skilled in the art.

According to the invention, TRANCE/RANK inhibitors useful in the invention to treat diseases characterized by bone loss may be formulated and administered in the manner taught *infra*, or by other techniques well known to those skilled in the art.

According to the invention, TRANCE/RANK inhibitors useful in the invention to  
25 treat diseases characterized by bone loss may be formulated and administered in the manner taught *infra*, or by other techniques well known to those skilled in the art. Some preferred dosages range from 1nM to 500mM. Some preferred dosages range from 1mM to 500mM. Some preferred dosages range from 1mg to 500 mg. Some preferred dosages range from 1000mg to 3000 mg. Some preferred dosages range from 1500 mg to 2500  
30 mg. According to the invention, TRANCE/RANK inhibitors are administered one to four times per day.

Pharmaceutical compositions according to the present invention comprise TRANCE/RANK inhibitors formulated in therapeutically effective doses. In some embodiments, the pharmaceutical composition is sterile and pyrogen free.

- Other aspects of the present invention include the use of TRANCE/RANK-
- 5 inhibitors in methods involving other cell types in which TRANCE/RANK-mediated signaling is involved in cell development and/or activity. Such cell types include antigen presenting cells such as dendritic cells and lymphocytes. Anderson *et al.* (Nature 390:175-179, 1997) refer to the RANK/RANKL in T cells and dendritic cells. Similarly, Kong *et al.* (Immunol. and Cell Biology 77:188-193, 1999) refer to osteoprotegerin ligand
- 10 as a common link between osteoclastogenesis, lymph node formation and lymphocyte development. In addition, Wong *et al.* (J. Leukocyte Biology 65:715-724, 1999) refer to TRANCE as regulating dendritic cell and osteoclast function. TRANCE/RANK inhibitors formulated in effective doses as described *supra* can be used to modulate dendritic cell maturation and function, T cell proliferation and CD40 receptor systems.
- 15 TNF exerts its biological activities by binding to two TNF-R: p55 and p75. A comparison of these receptors with several other cell surface receptors revealed certain shared structural features that led to their classification as a superfamily (Beutler *et al.*, Science 264:667, 1994). The TNF-R superfamily members possess characteristic extracellular Cys-rich domains, yet share only about 25% sequence homology. There are
- 20 at least ten members in this superfamily, including: TNF-R p55 and p75, TNF-R related protein (rp), CD40, Fas antigen (CD95), low-affinity nerve growth factor receptor (p74), CD27, CD30, 4-1BB and OX40 (Beutler *et al.*, Ann. NY Acad. Sci. pp. 118-133, 1994; Gruss and Dower, Cytokines and Mol. Ther. 1:75-105, 1995).

- Loops and turns in many proteins have been shown to play functionally important
- 25 roles in protein-protein interactions. In a specific embodiment illustrated by way of examples, *infra*, cyclic peptides were designed from three binding loops of TNF-R p55 which inhibited the binding of TNF to its cellular receptors. In particular, peptides designed from loop 1 of domain 3 exhibited the strongest inhibitory activities. When a peptide designed from this binding loop was used in combination with peptides designed
- 30 from two other loops, no further increase in inhibitory effects were observed, indicating that loop 1 of domain 3 is a dominate ligand binding site in TNF-R.

Based on this finding, corresponding regions of other TNF-R superfamily members from which inhibitory peptides and peptide analogues can be designed are readily identified by amino acid sequence alignment with the three specific binding sites of TNF-R p55 (Fig. 1). Since the dominate binding site of TNF-R p55 falls within amino acid residues #119 to 136, which sequence starts and ends with Cys, the same region in each TNF-R superfamily member may be used to design peptides and peptide analogues that are within the scope of the present invention. In cases where the regions do not start or end with Cys, the region may extend to then next Cys. For example, the corresponding region in Fas is deleted, and thus this region in starts at residue #97 and ends with #143. In the case of NGF-R, the region ends at the Cys at position at 135. Additionally, residues 74-81 and 97-110 may also be used to design additional peptides and peptide analogues within the scope of the present invention. Such compounds are then cyclized and modified at their termini with hydrophobic moieties as described in greater detail below.


Peptides and peptide analogues designed from binding loops of a TNF-R superfamily member

Generally, a compound used in the present invention is a cyclic peptide or peptide analogue, such as those disclosed in U.S. Application Serial No. 60/146,090, filed July 28, 1999, which is hereby incorporated by reference in its entirety. The peptide or peptide analogue is modified at its termini with hydrophobic moieties. In embodiments wherein the compound is a peptide, the peptide corresponds in primary sequence to a binding loop of a member of the TNF-R superfamily of a portion thereof. In a preferred embodiment, the peptide corresponds in primary sequence to a binding loop of TNF-R p55 or a portion thereof. In certain embodiments, one or more amino acid residues within the peptide are substituted with other amino acid residues. Typically, such amino acid substitutions are conservative, *i.e.*, the amino acid residues are replaced with other amino acid residues having physical and/or chemical properties similar to the residues they are replacing. Preferably, conservative amino acid substitutions are those wherein an amino acid is replaced with another amino acid encompassed within the same designated class, as will be described more thoroughly below. In embodiments wherein the compound is a peptide analogue, the analogue is obtained by replacing at least one amide linkage in the peptide



with a substituted amide or an isostere of amide.

In an illustrative embodiment, a compound used in the invention has the following formula:



(I)

5 wherein:

AC is a peptide of 3-18 amino acid residues, preferably 5-8 amino acid residues, which corresponds in primary sequence to a binding loop of a TNF-R and which may optionally contain conservative amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

10 AB<sub>1</sub> is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>2</sub> and a third functional group capable of forming a covalent linkage with AA<sub>1</sub> ;

15 AB<sub>2</sub> is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>1</sub> and a third functional group capable of forming a covalent linkage with AA<sub>2</sub>;




AA<sub>1</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>;

20 AA<sub>2</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

25 More specifically, the compounds of the invention are illustrated by three specific embodiments having the following formulae:

[illegible][illegible]

acids, naturally occurring non-genetically encoded L-amino acids, synthetic L-amino acids or D-enantiomers of all of the above. The amino acid notations used herein for the twenty genetically encoded L-amino acids and common non-encoded amino acids are conventional and are as follows:

5	Amino Acid	One-Letter Symbol	Common Abbreviation
	Alanine	A	Ala
	Arginine	R	Arg
	Asparagine	N	Asn
	Aspartic acid	D	Asp
10	Cysteine	C	Cys
	Glutamine	Q	Gln
	Glutamic acid	E	Glu
	Glycine	G	Gly
	Histidine	H	His
15	Isoleucine	I	Ile
	Leucine	L	Leu
	Lysine	K	Lys
	Methionine	M	Met
	Phenylalanine	F	Phe
20	Proline	P	Pro
	Serine	S	Ser
	Threonine	T	Thr
	Tryptophan	W	Trp
	Tyrosine	Y	Tyr
25	Valine	V	Val
	$\beta$ -alanine		bAla
	2,3-diaminopropionic acid		Dpr
	$\alpha$ -aminoisobutyric acid		Aib

5	N-Methylglycine (sarcosine)		MeGly
	Ornithine		Orn
	Citrulline		Cit
	t-buytlalanine		t-Bua
	t-butylglycine		t-Bug
10	N-methylisoleucine		Melle
	phenylglycine		Phg
	cyclohexylalanine		Cha
	Norleucine		Nle
	naphthylalanine		Nal
15	Pyridylalanine		
	3-benzothienyl alanine		
	4-chlorophenylalanine		Phe(4-Cl)
	2-fluorophenylalanine		Phe(2-F)
	3-fluorophenylalanine		Phe(3-F)
20	4-fluorophenylalanine		9
	Penicillamine		Pen
	1,2,3,4- tetrahydroisoquinoline-3- carboxylic acid		Tic
	$\beta$ -thienylalanine		Thi
	Methionine sulfoxide		MSO
25	Homoarginine		hArg
	N-acetyl lysine		AcLya
	2,4-diamino butyric acid		Dbu
	p-aminophenylalanine		Phe(pHN <sub>2</sub> )
	N-methylvaline		MeVal
	Homocysteine		hCys

Homoserine		hSer
$\epsilon$ -amino hexanoic acid		Aha

The compounds used in the invention are partially defined in terms of amino acid residues of designated classes. The amino acids may be generally categorized into three main classes: hydrophilic amino acids, hydrophobic amino acids and Cysteine-like amino acids, depending primarily on the characteristics of the amino acid side chain. These amino classes may be further divided into subclasses. Hydrophilic amino acids include amino acids having acidic, basic or polar side chains and hydrophobic amino acids including amino acids having aromatic or apolar side chains. Apolar amino acids may be further subdivided to include, among others, aliphatic amino acids. The definitions of the classes of amino acids as used herein are as follows:

“Hydrophobic Amino Acid” refers to an amino acid having a side chain that is uncharged at physiological pH and that is repelled by aqueous solution. Examples of genetically encoded hydrophobic amino acids include Ile, Leu and Val. Examples of non-genetically encoded hydrophobic amino acids include t-BuA.

“Aromatic Amino Acid” refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated  $\pi$ -electron system (aromatic group). The aromatic group may be further substituted with substituent groups such as alkyl, alkenyl, alkynyl, hydroxyl, sulfanyl, nitro and amino groups, as well as others. Examples of genetically encoded aromatic amino acids include phenylalanine, tyrosine and tryptophan. Commonly encountered non-genetically encoded aromatic amino acids include phenylglycine, 2-naphthylalanine,  $\beta$ -2-thienylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 4-chloro-phenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine and 4-fluorophenylalanine.

“Apolar Amino Acid” refers to a hydrophobic amino acid having a side chain that is generally uncharged at physiological pH and that is not polar. Examples of genetically encoded apolar amino acids include glycine, proline and methionine. Examples of non-encoded apolar amino acids include Cha.

“Aliphatic Amino Acid” refers to an apolar amino acid having a saturated or unsaturated straight chain, branched or cyclic hydrocarbon side chain. Examples of

genetically encoded aliphatic amino acids include Ala, Leu, Val and Ile. Examples of non-encoded aliphatic amino acids include Nle.

“Hydrophilic Amino Acid” refers to an amino acid having a side chain that is attracted by aqueous solution. Examples of genetically encoded hydrophilic amino acids include Ser and Lys. Examples of non-encoded hydrophilic amino acids include Cit and hCys.

“Acidic Amino Acid ” refers to a hydrophilic amino acid having a side chain pK value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Examples of genetically encoded acidic amino acids include aspartic acid (aspartate) and glutamic acid (glutamate).

“Basic Amino Acid” refers to a hydrophilic amino acid having a side chain pK value of greater than 7. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Examples of genetically encoded basic amino acids include arginine, lysine and histidine. Examples of non-genetically encoded basic amino acids include the non-cyclic amino acids ornithine, 2, 3-diaminopropionic acid, 2,4-diaminobutyric acid and homoarginine.

“Polar Amino Acid” refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which has a bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms. Examples of genetically encoded polar amino acids include asparagine and glutamine. Examples of non-genetically encoded polar amino acids include citrulline, N-acetyl lysine and methionine sulfoxide.

“Cysteine-Like Amino Acid” refers to an amino acid having a side chain capable of forming a covalent linkage with a side chain of another amino acid residue, such as a disulfide linkage. Typically, cysteine-like amino acids generally have a side chain containing at least one thiol (SH) group. Examples of genetically encoded cysteine-like amino acids include cysteine. Examples of non-genetically encoded cysteine-like amino acids include homocysteine and penicillamine.

As will be appreciated by those having skill in the art, the above classifications are not absolute -- several amino acids exhibit more than one characteristic property, and can therefore be included in more than one category. For example, tyrosine has both an

aromatic ring and a polar hydroxyl group. Thus, tyrosine has dual properties and can be included in both the aromatic and polar categories. Similarly, in addition to being able to form disulfide linkages, cysteine also has apolar character. Thus, while not strictly classified as a hydrophobic or apolar amino acid, in many instances cysteine can be used to confer hydrophobicity to a peptide.

Certain commonly encountered amino acids which are not genetically encoded of which the peptides and peptide analogues of the invention may be composed include, but are not limited to,  $\beta$ -alanine (B-Ala) and other omega-amino acids such as 3-aminopropionic acid (Dap), 2,3-diaminopropionic acid (Dpr), 4-aminobutyric acid and so forth;  $\alpha$ -aminoisobutyric acid (Aib);  $\epsilon$ -aminohyxyanoic acid (Aha);  $\delta$ -aminovaleric acid (Ava); N-methylglycine or sarcosine (MeGly); ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA); t-butylglycine (t-BuG); N-methylisoleucine (MeIle); phenylglycine (phg); cyclohexylalanine (Cha); norleucine (Nle); 2-naphthylalanine (2-Nal); 4-chlorophenylalanine (Phe(4-Cl)); 2-fluorophenylalanine (Phe(2-F)); 3-fluorophenylalanine (Phe(3-F)); 4-fluorophenylalanine (Phe(4-F)); penicillamine (Pen); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic);  $\beta$ -2-thienylalanine (Thi); methionine sulfoxide (MOS); homoarginine (hArg); N-acetyl lysine (AcLys); 2,3-diaminobutyric acid (Dab); 2,3-diaminobutyric acid (Dbu); *p*-aminophenylalanine (Phe(*p*NH<sub>2</sub>)); N-methyl valine (MeVal); homocysteine (hCys) and homoserine (hSer). These amino acids also fall conveniently into the categories defined above.

The classifications of the above-described genetically encoded and non-encoded amino acids are summarized in Table 1, below. It is to be understood that Table 1 is for illustrative purposes only and does not purport to be an exhaustive list of amino acid residues which may comprise the peptides and peptide analogues described herein. Other amino acid residues which are useful for making the peptides and peptide analogues described herein can be found, *e.g.*, in Fasman, 1989, CRC Practical Handbook of Biochemistry and Molecular Biology, CRC Press, Inc., and the references cited therein. Amino acids not specifically mentioned herein can be conveniently classified into the above-described categories on the basis of known behavior and/or their characteristic chemical and/or physical properties as compared with amino acids specifically identified.

Table 1

	Classification	Genetically Encoded	Genetically Non-Encoded
	Hydrophobic		
5	Aromatic	F, Y, W	Phg, Nal, Thi, Tic, Phe(4-Cl), Phe(2-F), Phe(3-F), Phe(4-F); Pyridyl Ala, Benzothienyl Ala
	Apolar	M, G, P	T-BuA, T-BuG, Melle, Nle,
10	Aliphatic	A, V, L, I Aib	MeVal, Cha, bAla, MeGly,
	Hydrophilic		
	Acidic	D, E	Dpr, Orn, hArg, Phe( <i>p</i> -NH <sub>2</sub> ),
15	Basic	H, K, R	DBU, A <sub>2</sub> BU
	Polar	Q, N, S, T, Y	Cit, AcLys, MSO, hSer
	Cysteine-Like	C	Pen, hCys, $\beta$ -methyl Cys

- 20 The designation Z<sub>n</sub> in each case represents an amino acid or other moiety capable of forming covalent linkages with other Z<sub>n</sub> so as to allow cyclization of the peptide. Examples of amino acid residues which are capable of forming covalent linkages with one another include cysteine-like amino acids such as Cys, hCys,  $\beta$ -methyl Cys and Pen, which are capable of forming disulfide bridges with one another. Preferred cysteine-like amino
- 25 acid residues include Cys and Pen.

- Amino acids used to cyclize a peptide need not be cysteine-like amino acids. Pairs of amino acids that have side chain functional groups capable of forming covalent linkages with one another can also be used. Such pairs of functional groups are known to those of skill in the art and include, *inter alia*, -COOH and -OH, -COOH and -NH<sub>2</sub>, and -COOH
- 30 and -SH. Thus, pairs of amino acids that can be used to cyclize a peptide include, *inter alia*, Asp and Lys; Glu and Lys; Asp and Arg; Glu and Arg; Asp and Ser; Glu and Ser; Asp and Thr; Glu and Thr; Asp and Cys; and Glu8 and Cys. Other pairs of amino acids which can be used to cyclize the peptide will be apparent to those skilled in the art.

- It will also be recognized that Z<sub>n</sub> groups used to cyclize a peptide need not be
- 35 amino acids. Thus, Z<sub>n</sub> may be any molecule having three functional groups -- one functional group capable of forming a covalent linkage with a terminus of the peptide, a



second functional group capable of forming a covalent linkage with the second functional group of another  $Z_n$ , and a third functional group capable of forming a covalent linkage with hydrophobic moieties  $B_n$ . Molecules having a suitable functional groups will be apparent to those skilled in the art. Examples of functional groups capable of forming a

5 covalent linkage with the amino terminus of a peptide include carboxylic acids and esters. Examples of functional groups capable of forming a covalent linkage with the carboxyl terminus of a peptide include -OH, -SH, -NH<sub>2</sub> and -NHR where R is (C<sub>1</sub> - C<sub>6</sub>) alkyl, (C<sub>1</sub> - C<sub>6</sub>) alkenyl and (C<sub>1</sub> - C<sub>6</sub>) alkynyl.

A variety of interlinkages useful to cyclize a peptide can be generated by reaction

10 between two  $Z_n$ .  $Z_n$  with functional groups suitable for forming such interlinkages, as well as reaction conditions suitable for forming such interlinkages, will be apparent to those of skill in the art. Preferably, the reaction conditions used to cyclize the peptides are sufficiently mild so as not to degrade or otherwise damage the peptide. Suitable groups for protecting the various functionalities as necessary are well known in the art (see, *e.g.*, Green

15 & Wuts, 1991, 2<sup>nd</sup> ed., John Wiley & Sons NY), as are various reaction schemes for preparing such protected molecules.

The destination  $B_n$  in each case represents a hydrophobic moiety. While not intending to be bound by any particular theory, it is believed that when placed in aqueous solution, these hydrophobic moieties interact so as to confer the peptide with structural

20 stability. A significant hydrophobic interaction for conferring structural stability is thought to be stacking of aromatic rings. Thus, in a preferred embodiment, such  $B_n$  designates a peptide of 1-6 amino acids, at least one of which is an aromatic amino acid or an aromatic or heteroaromatic moiety.  $B_n$  may be illustrated as  $X_{32} - X_{33} - X_{34} - X_{35} - X_{36} - X_{37}$  wherein  $X_n$  is an amino acid at least one of which is an aromatic amino acid. More preferably,  $X_{32} -$

25  $X_{33} - X_{34} - X_{35} - X_{36}$  are absent and  $X_{37}$  is an aromatic amino acid. Suitable aromatic amino acids include Tyr, Phe and Trp, with Tyr and Phe being preferred. Suitable aromatic or heteroaromatic moieties include phenyl, naphthyl, purine, pyrimidine, and the like.

In the peptides of formulae (II) - (IV), the symbol "-" between amino acid residues  $X_n$  generally designates a backbone interlinkage. Thus, the symbol "-" usually designates

30 an amide linkage (-C(O)-NH). It is to be understood, however, that in all of the peptides described in the specific embodiments herein, one or more amide linkages may optionally


be replaced with a linkage other than amide, preferably a substituted amide or an isostere of an amide linkage. Thus, while the various  $X_n$  have generally been described in terms of amino acids, one having skill in the art will recognize that in embodiments having non-amide linkages, the term "amino acid" refers to other bifunctional moieties having side-chain groups similar to the side chains of the amino acids. For example, in embodiments having non-amide linkages, the phrase "acidic amino acid" refers to a bifunctional molecule capable of forming the desired backbone interlinkages and which has a side chain group similar to the side chain of an acidic amino acid. Substituted amides generally include groups of the formula  $-C(O)-NR$ , where R is  $(C_1-C_6)$  alkyl,  $(C_1-C_6)$  alkenyl,  $(C_1-C_6)$  alkynyl, substituted  $(C_1-C_6)$  alkyl, substituted  $(C_1-C_6)$  alkenyl or substituted  $(C_1-C_6)$  alkynyl. Isosteres of amide generally include, but are not limited to,  $-CH_2NH-$ ,  $-CH_2S-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-$  (cis and trans),  $-C(O)CH_2-$  and  $-CH_2S-$ .

Compounds having such linkages and methods for preparing such compounds are well-known in the art (*see, e.g.*, Spatola, Vega Data 1 (3); **1983**, for a general review); Spatola, "Peptide Backbone Modifications" *In*: Chemistry and Biochemistry of Amino Acids Peptides and Proteins (Weinstein, ed.), Marcel Dekker, New York, p. 267 (general review) **1983**; Morley, Trends Pharm. Sci. 1:463-468, **1980**; Hudson *et al.*, Int. J. Prot. Res. 14:177-185 ( $-CH_2NH-$ ,  $-CH_2CH_2-$ ) **1979**; Spatola *et al.*, Life Sci. 38:1243-1249 ( $-CH_2-S-$ ), **1986**; Hann, J. Chem. Soc. Perkin Trans. I. 1:307-314 ( $-CH=CH-$ , cis and trans), **1982**; Jennings-White *et al.*, Tetrahedron. Lett. 23:1392-1398 ( $-COCH_2-$ ); European Patent Application EP 45665 (**1982**) CA:97:39405 ( $-CH(OH)CH_2-$ ); Holladay *et al.*, Tetrahedron Lett. 24:4401-4404, **1983**, ( $-C(OH)CH_2-$ ); and Hruby, Life Sci. 31:189-199, **1982** ( $-CH_2-S-$ ).

As will be discussed in more detail below, the interlinkage designated by " $\equiv$ " between residues  $B_n$  and/or  $Z_n$  and/or  $X_n$  in the compounds of formulae (II) - (IV) may also be a linker. Typically, a linker is a bifunctional molecule that spaces one moiety from another. Such linkers, which may be flexible, semi-rigid or rigid, are well-known in the art and include polypeptides such as poly-Gly and poly-Pro, bifunctional hydrocarbons such as aminocaproic acid,  $\delta$ -aminovaleric acid and  $\beta$ -alanine, carbohydrates, nucleic acids, and the like.

In one specific illustrative embodiment, the compounds of formula (II) are defined

as follows:



wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently a peptide of 1-6 amino acids, at least one of

- 5 which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;  
 $Z_2$  is a moiety that is capable of forming a covalent linkage with  $B_1$ ,  $X_3$  and  $Z_9$ ;  
 $Z_9$  is a moiety that is capable of forming a covalent linkage with  $B_{10}$ ,  $X_8$  and  $Z_2$ ;  
 $X_3$  is absent or a hydrophilic amino acid;  
 $X_4$  is a hydrophobic amino acid;  
10  $X_5$  is a hydrophilic amino acid;  
 $X_6$  is a hydrophilic amino acid;  
 $X_7$  is a hydrophobic or hydrophilic amino acid;  
 $X_8$  is a hydrophobic or hydrophilic amino acid;  
“-” is an amide, substituted amide or an isostere of amide thereof;  
15 “=” is a covalent linkage; and  
“≡” is a covalent linkage.

In a preferred embodiment of the invention, the compounds are those of formula

(II) wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently a peptide of 1-3 amino acids, at least one of

- 20** which is an aromatic amino acid;
- $Z_2$  and  $Z_9$  are each independently a Cys-like amino acid;
- $X_3$  is absent or an acidic amino acid;
- $X_4$  is an aromatic or apolar amino acid;
- $X_5$  is a polar amino acid;
- 25**  $X_6$  is a polar amino acid;

X<sub>7</sub> is an aromatic or polar amino acid;

X<sub>8</sub> is an aromatic, apolar or polar amino acid;

“-“ is an amide linkage;

“=” is a disulfide linkage; and

5 “≡” is an amide linkage.

In particularly preferred embodiment, the compounds used in the invention are those of formula (II) wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently Tyr or Phe;

Z<sub>2</sub> and Z<sub>9</sub> are each Cys;

10 X<sub>3</sub> is absent or Glu;

X<sub>4</sub> is Trp or Leu;

X<sub>5</sub> is Ser;

X<sub>6</sub> is Gln;

X<sub>7</sub> is Tyr or Asn;

15 X<sub>8</sub> is Tyr or Leu;

“-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

Particularly preferred peptides used in the invention include the following:


20 YCELSQYLCY (SEQ ID NO:12)

YC WSQNLCY (SEQ ID NO:13)

YC WSQNYCY (SEQ ID NO:14)

YC WSQYLCY (SEQ ID NO:15)

In a second illustrative embodiment, the compounds of formula (III) are defined as  
25 follows:



wherein:

B<sub>11</sub> and B<sub>22</sub> are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

**5**  $Z_{12}$  is a moiety that is capable of forming a covalent linkage with  $B_{11}$ ,  $X_{13}$  and  $Z_{21}$ ;

$Z_{21}$  is a moiety that is capable of forming a covalent linkage with  $B_{22}$ ,  $X_{20}$  and  $Z_{12}$ ;

X<sub>13</sub> is absent or hydrophobic amino acid;

X<sub>14</sub> is absent or a hydrophilic amino acid;

X<sub>15</sub> is a hydrophilic or hydrophobic amino acid;

10  $X_{16}$  is hydrophilic amino acid;

X<sub>17</sub> is absent or a hydrophobic amino acid;

X<sub>18</sub> is a hydrophilic amino acid;

X<sub>19</sub> is a hydrophilic amino acid;

X<sub>20</sub> is a hydrophilic amino acid;

**15** “-“ is an amide, a substituted amide or an isostere of amide thereof;

In a preferred embodiment, the compounds are those of formula (III) wherein:

B<sub>11</sub> and B<sub>22</sub> are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic amino acid;

Z<sub>12</sub> and Z<sub>21</sub> are each independently a Cys-like amino acid;

**20** X<sub>13</sub> is absent or an aromatic amino acid;

X<sub>14</sub> is absent or a polar amino acid;

X<sub>15</sub> is a basic, polar or apolar amino acid;

- X<sub>16</sub> is a polar amino acid;  
 X<sub>17</sub> is absent or an apolar amino acid;  
 X<sub>18</sub> is an acidic amino acid;  
 X<sub>19</sub> is a polar amino acid;  
**5** X<sub>20</sub> is a basic amino acid;  
 “-“ is an amide linkage;  
 “=” is a disulfide linkage; and  
 “≡” is an amide linkage.

In particularly preferred embodiment, the compounds are those of formula (III),

**10** wherein:

- B<sub>11</sub> and B<sub>22</sub> are each independently Tyr or Phe;  
 Z<sub>12</sub> and Z<sub>21</sub> are each Cys;  
 X<sub>13</sub> is absent or Phe;  
 X<sub>14</sub> is absent or Thr;  
**15** X<sub>15</sub> is Ala, Asn or Arg;  
 X<sub>16</sub> is Ser;  
 X<sub>17</sub> is absent or Val;  
 X<sub>18</sub> is Glu;  
 X<sub>19</sub> is Asn;  
**20** X<sub>20</sub> is Arg or His;  
 “-“ is an amide linkage;  
 “=” is a disulfide linkage; and  
 “≡” is an amide linkage.


Particularly preferred peptides used in the invention include the following:

- 25** YC FTASENH CY (SEQ. ID NO:16)  
 YC FTNSENH CY (SEQ. ID NO:17)  
 YC FTRSENH CY (SEQ. ID NO:18)  
 FC ASENH CY (SEQ. ID NO:19)  
 YC ASENH CY (SEQ. ID NO:20)  
**30** FC NSENH CY (SEQ. ID NO:21)  
 FC NSENR CY (SEQ. ID NO:22)

FC NSVENR CY

(SEQ. ID NO:23)

In a third illustrative embodiment, the compounds of formula (IV) are defined as follows:



**5** wherein:

B<sub>23</sub> and B<sub>33</sub> are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

$Z_{24}$  is a moiety that is capable of forming a covalent linkage with  $B_{23}$ ,  $X_{25}$  and  $Z_{32}$ ;

Z<sub>32</sub> is a moiety that is capable of forming a covalent linkage with B<sub>33</sub>, X<sub>31</sub> and Z<sub>24</sub>;

**10** X<sub>25</sub> is absent or a hydrophilic amino acid;

X<sub>26</sub> is a hydrophilic amino acid;

X<sub>27</sub> is a hydrophilic amino acid;

X<sub>28</sub> is a hydrophobic amino acid;

X<sub>79</sub> is a hydrophobic amino acid;

**15** X<sub>30</sub> is absent or a hydrophilic amino acid;

X<sub>31</sub> is absent or a hydrophobic amino acid;

“-“ is an amide, a substituted amide or an isostere of amide;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

20 In a preferred embodiment, the compounds are those of formula (IV) wherein:

B<sub>23</sub> and B<sub>33</sub> are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic acid;

$Z_{24}$  and  $Z_{32}$  are each independently a Cys-like amino acid;

- 5       X<sub>25</sub> is absent or a basic amino acid;  
      X<sub>26</sub> is a basic amino acid;  
      X<sub>27</sub> is an acidic amino acid;  
      X<sub>28</sub> is an apolar amino acid;  
      X<sub>29</sub> is an apolar amino acid;  
      X<sub>30</sub> is absent or a polar amino acid;  
      X<sub>31</sub> is absent or a apolar amino acid;  
      “-“ is an amide linkage;  
      “=” is a disulfide linkage; and  
10       “≡” is an amide linkage.

In a particularly preferred embodiment, the compounds used in the invention or analogues thereof are those of formula (IV), wherein:

- 15       B<sub>23</sub> and B<sub>33</sub> are each independently Tyr or Phe;  
      Z<sub>24</sub> and Z<sub>32</sub> are each Cys;  
      X<sub>25</sub> is absent or Arg;  
      X<sub>26</sub> is Lys;  
      X<sub>27</sub> is Glu;  
      X<sub>28</sub> is Leu, Pro or Met;  
      X<sub>29</sub> is Gly;  
20       X<sub>30</sub> is absent or Gln;  
      X<sub>31</sub> is absent or Val;  
      “-“ is an amide linkage;  
      “=” is a disulfide linkage; and  
      “≡” is an amide linkage.

- 25       Particularly preferred peptides used in the invention include the following:

YC RKELGOV CY	(SEQ. ID NO:24)
YC KEPGQ CY	(SEQ. ID NO:25)
YC RKEMG CY	(SEQ. ID NO:26)
FC RKEMG CY	(SEQ. ID NO:27)

- 30       In all of the aforementioned embodiments of the invention, it is to be understood that the phrase “amino acid” also refers to bifunctional moieties having amino acid-like



side chains, as previously described.

Generally, active peptides or peptide analogues used in the invention are those that exhibit at least about 15% inhibition of TNF-R:TNF interactions as measured in *vitro* assays such as those described, *infra*. Preferably, active peptides used in the invention or  
5 analogues thereof will exhibit at least about 20% to 50% or even 80% or more inhibition of TNF-R:TNF- $\alpha$  binding interactions.

### Preparation Of Peptides And Peptide Analogues

#### Chemical Synthesis

10 The peptides used in the invention or analogues thereof, may be prepared using virtually any art-known technique for the preparation of peptides and peptide analogues. For example, the peptides may be prepared in linear or non-cyclized form using conventional solution or solid phase peptide syntheses and cyclized using standard chemistries. Preferably, the chemistry used to cyclize the peptide will be sufficiently mild  
15 so as to avoid substantially degrading the peptide. Suitable procedures for synthesizing the peptides described herein as well as suitable chemistries for cyclizing the peptides are well known in the art.

Formation of disulfide linkages, if desired, is generally conducted in the presence of mild oxidizing agents. Chemical, enzymatic or photolytic oxidation agents may be  
20 used. Various methods are known in the art, including those described, for example, by Tam, J.P. *et al.*, Synthesis 955-957, **1979**; Stewart *et al.*, Solid Phase Peptide Synthesis. 2d Ed., Pierce Chemical Company Rockford, IL, **1984**; Ahmed *et al.*, J. Biol. Chem. 250:8477-8482, **1975**; and Pennington *et al.* Peptides 1990 164-166, Giralt and Andreu, Eds., ESCOM, **1991**; Leiden, The Netherlands. An additional alternative is described by  
25 Kamber *et al.*, Helv Chim Acta, 63:899-915, **1980**. A method conducted on solid supports is described by Albericio, Int.J. Peptide Protein Res., 26:92-97, **1985**. Any of these methods may be used to form disulfide linkages in the peptides of the invention. Preferred methods for effecting disulfide-bridge formation for the peptides described herein are provided in the examples.

#### 30 Recombinant Synthesis

If the peptide is composed entirely of gene-encoded amino acids, or a portion of it is so composed, the peptide or the relevant portion may also be synthesized using conventional recombinant genetic engineering techniques. The isolated peptides, or segments thereof, are then condensed, and oxidized, as previously described, to yield a  
5 cyclic peptide.

For recombinant production, a polynucleotide sequence encoding a linear form of the peptide is inserted into an appropriate expression vehicle, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence, or in the case of an RNA viral vector, the necessary elements for replication and  
10 translation. The expression vehicle is then transfected into a suitable target cell which will express the linear form of the cyclic peptide. Depending on the expression system used, the expressed peptide is then isolated by procedures well-established in the art. Methods for recombinant protein and peptide production are well known in the art (see, *e.g.*, Maniatis *et al.*, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory,  
15 N.Y., 1989; and Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y., 1989).

A variety of host-expression vector systems may be utilized to express the peptides described herein. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage DNA or plasmid DNA expression vectors  
20 containing an appropriate coding sequence; yeast or filamentous fungi transformed with recombinant yeast or fungi expression vectors containing an appropriate coding sequence; insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus) containing an appropriate coding sequence; plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus or Tobacco mosaic virus) or  
25 transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing an appropriate coding sequence; or animal cell systems.

The expression elements of the expression systems vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, may  
30 be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage  $\lambda$ , plac, ptrp, ptac (ptrp-lac hybrid

promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedron promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells (*e.g.*, heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll a/b binding protein) or from plant viruses (*e.g.*, the 35S RNA promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in mammalian cell systems, promoters derived from the genomes of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the adenovirus late promoter; the vaccinia virus 7.5 K promoter) may be used; when generating cell lines that contain multiple copies of expression product, SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

In cases where plant expression vectors are used, the expression of sequences encoding the peptides of the invention may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brisson *et al.*, Nature 310: 511-514, 1984), or the coat protein promoter of TMV (Takamatsu *et al.*, EMBO J., 6:307-311, 1987) may be used; alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi *et al.*, EMBO J. 3:1671-1680, 1984; Broglie *et al.*, Science 224:838-843, 1984) or heat shock promoters, *e.g.*, soybean hsp17.5-E or hsp17.3-B (Gurley *et al.*, Mol. Cell. Biol. 6:599-565, 1986) may be used. These constructs can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of such techniques see, *e.g.*, Weissbach & Weissbach, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp. 421-463, 1988; and Grierson & Corey, Plant Molecular Biology, 2<sup>nd</sup> Ed., Blackie, London, Ch. 7-9, 1988.

In one insect expression system that may be used to produce the peptides of the invention, *Autographa californica* nuclear polyhidrosis virus (AcNPV) is used as a vector to express the foreign genes. The virus grows in *Spodoptera frugiperda* cells. A coding sequence may be cloned into non-essential regions (for example the polyhedron gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedron promoter). Successful insertion of a coding sequence will result in inactivation of the polyhedron gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedron gene). These recombinant viruses are then

used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed. (e.g., see Smith *et al.*, J. Virol., 46:584, 1983; Smith, U.S. Patent No. 4,215,051). Further examples of this expression system may be found in Current Protocols in Molecular Biology, Vol. 2, Ausubel *et al.*, eds., Greene Publish. Assoc. & Wiley Interscience.

- 5 In mammalian host cells, a number of viral based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a coding sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential
- 10 region of the viral genome (e.g. Region E1 or E3) will result in a recombinant virus that is viable and capable of expressing peptide in infected hosts. (e.g., See Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:3655-3659, 1984). Alternatively, the vaccinia 7.5 K promoter may be used, (see, e.g., Mackett *et al.*, Proc. Natl. Acad. Sci. USA, 79:7415-7419, 1982; Mackett *et al.*, J. Virol., 49:857-864, 1984; Panicali *et al.*, Proc. Natl. Acad. Sci. 79:4927-
- 15 4931, 1982).

Other expression systems for producing linear or non-cyclized forms of the cyclic peptides used in the invention will be apparent to those having skill in the art.

#### Purification of the Peptides and Peptide Analogues

- The peptides and peptide analogues used in the invention can be purified by art-
- 20 known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography and the like. The actual conditions used to purify a particular peptide or analogue will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, *etc.*, and will be apparent to those having skill in the art.
- 25 For affinity chromatography purification, any antibody which specifically binds the peptides or peptide analogues may be used. For the production of antibodies, various host animals, including but not limited to rabbits, mice, rats, etc., may be immunized by injection with a linear or cyclic peptide. The peptide may be attached to a suitable carrier, such as BSA, by means of a side chain functional group or linkers attached to a side chain
- 30 functional group. Various adjuvants may be used to increase the immunological response,

depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacilli

5 Calmette-Duerin) and *Corynebacterium parvum*.

Monoclonal antibodies to a peptide may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture.

These include but are not limited to the hybridoma technique originally described by

Koehler and Milstein, *Nature*, 256:495-497, 1975; the human B-cell hybridoma technique,

10 Kosbor *et al.*, *Immunology Today*, 4:72, 1983; Cote *et al.*, *Proc. Natl. Acad. Sci., USA*,

80:2026-2030, 1983; and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal*

*Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)). In addition,

techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, *Proc.*

*Natl. Acad. Sci., USA*, 81: 6851-6855, 1984; Neuberger *et al.*, *Nature*, 312:604-608, 1984;

15 Takada *et al.*, *Nature*, 314:452-454, 1985) by splicing the genes from a mouse antibody

molecule of appropriate antigen specificity together with genes from a human antibody

molecule of appropriate biological activity can be used. Alternatively, techniques

described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be

adapted to produce cyclic peptide-specific single chain antibodies.

20 Antibody fragments which contain deletions of specific binding sites may be

generated by known techniques. For example, such fragments include but are not limited

to F(ab')<sub>2</sub> fragments, which can be produced by pepsin digestion of the antibody molecule

and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub>

fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*,

25 *Science* 246: 1275-1281, 1989) to allow rapid and easy identification of monoclonal Fab

fragments with the desired specificity for the cyclic peptide of interest.

The antibody or antibody fragment specific for the desired cyclic peptide can be

attached, for example, to agarose, and the antibody-agarose complex is used in

immunochromatography to purify cyclic peptides of the invention. See, Scopes, Protein

30 Purification: Principles and Practice, Springer-Verlag New York, Inc., NY, 1984;

Livingstone, Methods Enzymology: Immunoaffinity Chromatography of Proteins 34:723-

731, 1974.

#### Formulation and Route of Administration

The compounds of the invention, may be administered to a subject *per se* or in the form of a pharmaceutical composition. Pharmaceutical compositions comprising the

- 5 compounds of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiological acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active peptides or peptide
- 10 analogues into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For topical administration the compounds of the invention may be formulated as solutions, gels, ointments, creams, suspensions, *etc.* as are well-known in the art.

- Systemic formulations include those designed for administration by injection, *e.g.*
- 15 subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.

- For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory
- 20 agents such as suspending, stabilizing and/or dispersing agents.

Alternatively, the compounds may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

- 25 For oral administration, the compounds can be readily formulated by combining the active peptides or peptide analogues with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. For oral solid formulations such as, for example,
- 30 powders, capsules and tablets, suitable excipients include fillers such as sugars, such as

lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium, carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired,

- 5 disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, atgar, or alginic acid or a salt thereof such as sodium alginate.

If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques.

- For oral preparations such as, for example, suspensions, elixirs and solutions,  
10 suitable carriers, excipients or diluents include water, glycols, oils, alcohols, *etc.* Additionally, flavoring agents, preservatives, coloring agents and the like may be added.

For buccal administration, the compounds may take the form of tablets, lozenges, *etc.* formulated in conventional manner.

- For administration by inhalation, the compounds for use according to the present  
15 invention are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.* gelatin for use in an inhaler or  
20 insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

- 25 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion  
30 exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Alternatively, other pharmaceutical delivery systems may be employed. Liposomes and emulsions are well known examples of delivery vehicles that may be used to deliver peptides and peptide analogues of the invention. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity.

- 5 Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and
- 10 the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

- As the compounds of the invention may contain charged side chains or termini, they may be included in any of the above-described formulations as the free acids or bases or as pharmaceutically acceptable salts. Pharmaceutically acceptable salts are those salts
- 15 which substantially retain the antimicrobial activity of the free bases and which are prepared by reaction with inorganic acids. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.

#### Effective Dosages

- The compounds of the invention will generally be used in an amount effective to
- 20 achieve the intended purpose. For use to treat or prevent osteoclastogenesis or osteoclast activity, the compounds of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. By therapeutically effective amount is meant an amount which is effective to ameliorate, or prevent the symptoms of the disease or disorder, or prolong the survival of the patient being treated. Determination
- 25 of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

- For systemic administration, a therapeutically effective dose can be estimated initially from *in vitro* assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC<sub>50</sub> as determined in cell
- 30 culture (*i.e.*, the concentration of test compound that inhibits 50% of TNF-R: TNF-binding



interactions). Such information can be used to more accurately determine useful doses in humans.

Initial dosages can also be estimated from *in vivo* data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily  
5 optimize administration to humans based on animal data.

Dosage amount and interval may be adjusted individually to provide plasma levels of the compounds which are sufficient to maintain therapeutic effect. Usual patient dosages for administration by injection range from about 0.1 to 5 mg/kg/day, preferably from about 0.5 to 1 mg/kg/day. Therapeutically effective serum levels may be achieved by  
10 administering multiple doses each day.

In cases of local administration or selective uptake, the effective local concentration of the compounds may not be related to plasma concentration. One having skill in the art will be able to optimize therapeutically effective local dosages without undue experimentation.

15 The amount of compound administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

### Toxicity

Preferably, a therapeutically effective dose of the compounds described herein will  
20 provide therapeutic benefit without causing substantial toxicity.

Toxicity of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD<sub>50</sub> (the dose lethal to 50% of the population) or the LD<sub>100</sub> (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic  
25 index. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulation a dosage range that is not toxic for use in human. The dosage of the compounds described herein lies preferably within a range of circulating concentrations that include the effective dose with little or not toxicity. The dosage may vary within this range depending upon the  
30 dosage form employed and the route of administration utilized. The exact formulation,

route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, *e.g.*, Fingl *et al.*, In: The Pharmacological Basis of Therapeutics, Ch.1, p.1, 1975).

The invention having been described, the following examples are offered by way of  
5 illustration and not limitation.

## EXAMPLES

### Example 1

Recently, therapeutic peptidomimetics that interfere with the TNF/TNF receptor  
10 interaction have been developed based on atomic structures deduced from the crystal structures of TNF- $\alpha$  and the TNF $\beta$ /TNF receptor complex (Takasaki *et al.* Nature Biotechnology, 15:1266-1270, 1997). The most critical TNF- $\alpha$  recognition site was localized to the first loop of the third domain of TNF receptor (residues 107-114). A peptidomimetic (WP9QY) engineered to mimic this recognition site efficiently  
15 antagonized the effects of TNF-binding to the TNF- $\alpha$  receptor in L929 lymphocytes.

WP9QY peptide was tested at concentrations ranging from about 5  $\mu$ M to about 500  $\mu$ M for its effect on osteoclast formation using the co-culture system induced by 1,25OH<sub>2</sub>D<sub>3</sub> (1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>) and PGE<sub>2</sub>. Osteoclastogenesis was dose- and time-dependently inhibited by the peptide WP9QY (IC<sub>50</sub> = 250  $\mu$ M), but this IC<sub>50</sub> was  
20 50-fold higher than what was required for the TNF/TNF receptor interaction (5 $\mu$ M). This difference suggests that the WP9QY peptide inhibits osteoclastogenesis by interfering not with the TNF/TNF receptor interaction but with another related ligand-receptor pair such as TRANCE/RANK. This was confirmed by demonstrating that WP9QY inhibits TRANCE-induced marrow cultures. There was a reciprocal dose-dependence of WP9QY  
25 and TRANCE. Thus, WP9QY is capable of interfering not only with the TNF/TNF receptor interaction but also with the RANK Ligand/RANK interaction, thereby decreasing the osteoclastogenic potential of this cytokine.

### Example 2

#### Materials and Methods

30 Human recombinant TNF- $\alpha$  and <sup>125</sup>I-labeled TNF- $\alpha$  were obtained from Amersham

Life Science, Inc. (Arlington Heights, IL). TNF-R(I) or p55 extracellular domain-IgG heavy chain chimeric protein was prepared by expression of a cDNA construct (Peppel *et al.*, J. Exp. Med. 174:1483, 1991; Williams *et al.*, Immunol. 84:433, 1995). Anti-TNF- $\alpha$  monoclonal antibody was prepared according to Doring *et al.* (Molecular Immunol.

- 5 31:1059, 1994) and anti-TNF-R(I) monoclonal antibody (htr-9) was obtained from BMA Biomedicals AG (Augst, Switzerland).

### Molecular Modeling

Computer modeling was performed using Quanta 4.0 (Molecular Simulation Inc., MA). The model peptides were constructed from their sequences and folded using

- 10 CHARMM. The side chains of amino acid residues were first positioned to permitted conformation using Ponders rotamer (Ponder *et al.*, J. Mol. Biol. 193:775-791, 1987) database provided in QUANTA. Then, the folded peptides were minimized to convergence with the dielectric constant set to 80.

- The crystal structure of the TNF- $\beta$ /TNF-R(I) complex (Banner *et al.*, Cell 73:431, 15 1993) was utilized to determine the binding sites of TNF-R for TNF- $\alpha$ . The first (residues 56-73) and second (residues 76-83) loops of domain 2 and the first loop (residues 107-114) of domain 3 of the TNF-R were explored for use in designing peptides. The essential amino acid sequences of TNF-R for binding interactions with TNF- $\alpha$  were identified as structural templates by superimposing TNF- $\alpha$  to TNF- $\beta$  complexed with its cognate 20 receptor. Then, 5-8 amino acid-long peptides derived from TNF-R as shown in Table 2 were used as templates for the design of exocyclic peptides. Additional peptides were derived from CDR sequences of a light chain of an anti-TNF- $\alpha$  neutralizing antibody, CDR1L of Di62 (Doring *et al.*, Mol. Immunol. 31:1059, 1994). Exocyclic modifications such as peptide cyclization and addition of aromatic amino acids such as Phe and Tyr to 25 the ends of each peptide were performed as described (Zhang *et al.*, Nature Biotech. 14:472, 1996; Zhang *et al.*, Nature Biotech 15:150, 1997).

### Peptide Synthesis, Cyclization and Purification

Linear peptides were synthesized by solid-phase methods, deprotected, and released from the resin utilizing standard methodology well known to those skilled in the

art. Peptides were precipitated and purified by high performance liquid chromatography (HPLC) utilizing a C18 column and then lyophilized. The purity of such peptides was greater than 95% as measured by HPLC analysis.

5 The peptides containing internal Cys residues were oxidized by dissolving them at 100 µg/ml in distilled water adjusted or buffered to pH 8.0 - 8.5, for example, by (NH<sub>4</sub>)<sub>2</sub>CO<sub>3</sub> with stirring and exposure to air at 4°C for <10 days until 95% formation of intramolecular disulfide bonds had been confirmed by DTNB (Sigma, St. Louis, MO) which determined free sulfhydryls in peptides (Habeeb, Anal. Bioch. 56:60, 1973; Angeletti *et al.*, In Techniques in Protein Chemistry VII, Ed. Marsak, Academic Press, San 10 Diego, CA., pp. 81-91, 1996). Briefly, peptides (100 µg/ml, 50 µl) and DTNB (10mM, 50 µl) were added to 0.1 M sodium phosphate buffer (pH 8.0, 1 ml), incubated in the dark for 30 minutes, and the absorbance at 420 nm was determined and compared with the linear unoxidized peptides.

15 The cyclized peptides were lyophilized, purified by HPLC utilizing a C18 preparative column and a size exclusion column Protein-Pak 60 (Waters, Milford, MA). The purity of the peptides was shown to be greater than 95% by HPLC analysis. The concentration of each cyclized peptide was calculated based on UV intensity versus the corresponding linear peptide by HPLC analysis.

20 Amino acid sequences corresponding to three TNF-α-binding loops of TNF-R were used as templates for the synthesis of a number of peptides. Cys residues were included in the linear peptides to enable their cyclization. Their identity was verified by mass spectrometry. Various exocyclic peptides are listed in Table 2.

Table 2

Amino Acid Sequences of TNF- $\alpha$  Binding Sites in TNF-R and Exocyclic Peptides  
Derived from These Sites.

5	TNF- $\alpha$ Binding Sites in the Receptor	Name	Exocyclic Peptides*	S.I.D. #
	<b>Binding Site - 5</b>			
	TNF- $\alpha$	WP5	YC FTASENH CY	16
	53E 82R 85VSY87 125Q 127E	WP5N	YC FTNSENH CY	17
		WP5R	YC FTRSENH CY	18
10	Receptor (loop 1 of domain 2)	WP5J	FC ASENH CY	19
	60 FTASENH 66	WP5JY	YC ASENH CY	20
		WP5JN	FC NSENH CY	21
		WP5JR	FC NSENR CY	22
		WP5VR	FC NSVENR CY	23
15		WP1**	YC SQSVSND CF	28
		WP1R**	FC VSNDR CY	29
	<b>Binding site - 8</b>			
	TNF- $\alpha$			
20	65K 67Q 113P 115Y 143L 145A	WP8L	YC RKELGQV CY	24
	Receptor (loop 2 of domain 2)	WP8JP	YC KEPGQ CY	25
	76 CRKEMGOV 83	WP8J	YC RKEMG CY	26
		WP8JF	FC RKEMG CY	27
25	<b>Binding site - 9</b>			
	TNF- $\alpha$			
	72THVL75 77T 97I 137 N	WP9Q	YC WSQNL CY	13
30	Receptor (loop 1 of domain 3)	WP9ELY	YCELSQYL CY	12
	107 WSENL 111	WP9Y	YC WSQNY CY	14
		WP9QY	YC WSQYL CY	15

\* Peptides were cyclized with cysteine disulfide bridges

35 \*\* WP1 and WP1R were derived from an anti-TNF- $\alpha$  antibody (Di62, CDR1L) and the template sequence is QSVSNDV.

### Example 3

#### Identification of Osteoclasts Formed *in Vitro*

TRAP refers to tartrate resistant acid phosphatase which identifies osteoclast-like  
40 cells. Osteoprotegerin (OPG) is a naturally occurring secreted protein with homology to  
members of the TNF receptor family. Administration of OPG *in vivo* inhibits  
osteoclastogenesis and associated bone resorption and blocks the pathological increase in

osteoclast numbers and activity seen in animal models that mimic osteopenic disorders in humans. OPG can be used as a positive control in the TRAP assay.

Cytochemical staining for TRAP is widely used for identifying osteoclasts *in vivo* and *in vitro*. Naphthol AS-MX phosphate 5 mg. Sigma, St. Louis, MO) is resolved in 0.5  
5 ml of N, N-dimethylformamide (Wako). Thirty milligrams of fast red violet LB salt (Sigma) and 50 ml of 0.1 M sodium acetate buffer (pH 5.0) containing 50 mM sodium tartrate are added to the mixture (the TRAP-staining solution). Cells are fixed with 3.7% (v/v) formaldehyde in Ca<sup>2+</sup>- and Mg<sup>2+</sup>-free phosphate-buffered saline [PBS(-)] for 10 min. fixed again with ethanol-acetone (50:50, v:v) for 1 min. and incubated with the TRAP-  
10 staining solution for 10 min. at room temperature. TRAP-positive osteoclasts appear as red cells. The incubation period longer than 10 min. should be avoided since cells other than osteoclasts become weakly positive with time. After staining, cells are washed with distilled water, and TRAP-positive multinucleated cells having three or more nuclei are counted as osteoclasts under a microscope. (G.C. Nicholson, J.M. Mosely, P.M. Sexton,  
15 F.A.O. Mendelssohn, and T.J. Martin, *J. Clin. Invest.* 78, 355, 1986, which is incorporated herein by reference).


The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention and any sequences which are functionally equivalent are within the scope of the invention. Indeed, various  
20 modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

## CLAIMS

1. A method of inhibiting osteoclastogenesis comprising the step of administering to a patient an amount of an inhibitor effective to inhibit osteoclastogenesis.
2. The method of claim 1 wherein the inhibitor has the formula:

5



(I)

wherein:

- AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally contain one or more amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

- AB<sub>1</sub> is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>2</sub> and a third functional group capable of forming a covalent linkage with AA<sub>1</sub>;


- AB<sub>2</sub> is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>1</sub> and a third functional group capable of forming a covalent linkage with AA<sub>2</sub>;

- AA<sub>1</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>;

AA<sub>2</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>;

[illegible][illegible]

- [illegible]

[illegible][illegible]

- [illegible]



6. The method of Claim 5, wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently a peptide of 1-2 amino acids, at least one of which is an aromatic amino acid ;

Z<sub>2</sub> and Z<sub>9</sub> are each independently a Cys-like amino acid;

5 X<sub>3</sub> is absent or an acidic amino acid;

X<sub>4</sub> is an aromatic or apolar amino acid;

X<sub>5</sub> is a polar amino acid;

X<sub>6</sub> is a polar amino acid;

X<sub>7</sub> is an aromatic or polar amino acid;

10 X<sub>8</sub> is an aromatic, apolar or polar amino acid;

“-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

6. The method of Claim 5, wherein:

15 B<sub>1</sub> and B<sub>10</sub> are each independently Tyr or Phe;

Z<sub>2</sub> and Z<sub>9</sub> are each Cys;

X<sub>3</sub> is absent or Glu;

X<sub>4</sub> is Trp or Leu;

X<sub>5</sub> is Ser;

20 X<sub>6</sub> is Gln;

X<sub>7</sub> is Tyr or Asn;

X<sub>8</sub> is Tyr or Leu;

“-” is an amide linkage;

“=” is a disulfide linkage; and

25 “≡” is an amide linkage.

8. The method of Claim 7, wherein said inhibitor is selected from the group consisting of WP9Q - SEQ ID NO:13, WP9ELY - SEQ ID NO:12, WP9Y - SEQ ID NO:14, and WP9QY - SEQ ID NO:15.


9. The method of Claim 4, wherein the inhibitor has the formula:



- 5**         $Z_{12}$  and  $Z_{21}$  are each independently a Cys-like amino acid;  
           $X_{13}$  is absent or an aromatic amino acid;  
           $X_{14}$  is absent or a polar amino acid;  
           $X_{15}$  is a basic, polar or apolar amino acid;  
           $X_{16}$  is a polar amino acid;  
           $X_{17}$  is absent or an apolar amino acid;  
           $X_{18}$  is an acidic amino acid;  
           $X_{19}$  is a polar amino acid;  
           $X_{20}$  is a basic amino acid;
- 10**        “-“ is an amide linkage;  
          “=” is a disulfide linkage; and  
          “≡” is an amide linkage.
- 11.**       The method of Claim 10, wherein:
- 15**         $B_{11}$  and  $B_{22}$  are each independently Tyr or Phe;  
           $Z_{12}$  and  $Z_{21}$  are each Cys;  
           $X_{13}$  is absent or Phe;  
           $X_{14}$  is absent or Thr;  
           $X_{15}$  is Ala, Asn or Arg;  
           $X_{16}$  is Ser;
- 20**         $X_{17}$  is absent or Val;  
           $X_{18}$  is Glu;  
           $X_{19}$  is Asn;  
           $X_{20}$  is Arg or His;  
          “-“ is an amide linkage;
- 25**        “=” is a disulfide linkage; and  
          “≡” is an amide linkage.
- 12.**       The method of Claim 11, wherein said inhibitor is selected from the group consisting of WP5 - SEQ ID NO:16, WP5N - SEQ ID NO:17, WP5R - SEQ ID NO:18, WP5J - SEQ ID NO:19, WP5JY - SEQ ID NO:20, WP5JN - SEQ ID NO:21, WP5JR -

SEQ ID NO:22, and WP5VR - SEQ ID NO:23.

13. The method of Claim 4, wherein the inhibitor has the formula:



wherein:

- 5           B<sub>23</sub> and B<sub>33</sub> are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
- Z<sub>24</sub> is a moiety that is capable of forming a covalent linkage with B<sub>23</sub>, X<sub>25</sub> and Z<sub>32</sub>;
- Z<sub>32</sub> is a moiety that is capable of forming a covalent linkage with B<sub>33</sub>, X<sub>31</sub> and Z<sub>24</sub>;
- X<sub>25</sub> is absent or a hydrophilic amino acid;
- 10          X<sub>26</sub> is a hydrophilic amino acid;
- X<sub>27</sub> is a hydrophilic amino acid;
- X<sub>28</sub> is a hydrophilic amino acid;
- X<sub>29</sub> is a hydrophilic amino acid;
- X<sub>30</sub> is absent or a hydrophilic amino acid;
- 15          X<sub>31</sub> is absent or a hydrophilic amino acid;
- “-“ is an amide, a substituted amide or an isostere of amide;
- “=” is a covalent linkage; and
- “≡” is a covalent linkage.
14.       The method of Claim 13, wherein:
- 20          B<sub>23</sub> and B<sub>33</sub> are each independently a peptide of 1-3 amino acids, at least one of

which is an aromatic amino acid;

$Z_{24}$  and  $Z_{32}$  are each independently a Cys-like amino acid;

$X_{25}$  is absent or a basic amino acid;

$X_{26}$  is a basic amino acid;

5  $X_{27}$  is an acidic amino acid;

$X_{28}$  is an apolar amino acid;

$X_{29}$  is an apolar amino acid;

$X_{30}$  is absent or a polar amino acid;

$X_{31}$  is absent or an apolar amino acid;

10 “-“ is an amide linkage’

“=” is a disulfide linkage; and

“≡” is an amide linkage.

15. The method of Claim 14, wherein:

$B_{23}$  and  $B_{33}$  are each independently Tyr or Phe;

15  $Z_{24}$  and  $Z_{32}$  are each Cys;

$X_{25}$  is absent or Arg;

$X_{26}$  is Lys;

$X_{27}$  is Glu;

$X_{28}$  is Ieu, Pro or Met;

20  $X_{29}$  is Gly;

$X_{30}$  is absent or Gln;

$X_{31}$  is absent or Val;

“-“ is an amide linkage;


“=” is a disulfide linkage; and

25 “≡” is an amide linkage.

16. The method of Claim 15, wherein said inhibitor is selected from the group consisting of WP8L - SEQ ID NO:24, WP8JP - SEQ ID NO:25, WP8J - SEQ ID NO:26, and WP8JF - SEQ ID NO:27.

17. A method of treating patients who have diseases characterized by bone loss comprising the step of administering to said patient an amount of an inhibitor effective to inhibit such bone loss.

18. The method of claim 17 wherein said inhibitor is a compound having the formula:



wherein:

AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally contain one or more amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

AB<sub>1</sub> is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>2</sub> and a third functional group capable of forming a covalent linkage with AA<sub>1</sub>;

AB<sub>2</sub> is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>1</sub> and a third functional group capable of forming a covalent linkage with AA<sub>2</sub>;


AA<sub>1</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>1</sub>;

AA<sub>2</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

19. The method of claim 18 wherein the inhibitor has the formula:



wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

Z<sub>2</sub> is a moiety that is capable of forming a covalent linkage with B<sub>1</sub>, X<sub>3</sub> and Z<sub>9</sub>;

Z<sub>9</sub> is a moiety that is capable of forming a covalent linkage with B<sub>10</sub>, X<sub>8</sub> and Z<sub>7</sub>;

X<sub>3</sub> is absent or a hydrophilic amino acid;

X<sub>4</sub> is a hydrophobic amino acid;

10 X<sub>5</sub> is a hydrophilic amino acid;

X<sub>6</sub> is a hydrophilic amino acid;

X<sub>7</sub> is a hydrophobic or hydrophilic amino acid;

X<sub>8</sub> is a hydrophobic or hydrophilic amino acid;

“-” is an amide, substituted amide or an isostere of amide thereof;

15           “=” is a covalent linkage; and

“≡” is a covalent linkage.

20. The method of claim 19 wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic amino acid;

20  $Z_2$  and  $Z_9$  are each independently a Cys-like amino acid;

X<sub>3</sub> is absent or an acidic amino acid;

X<sub>4</sub> is an aromatic or apolar amino acid;

X<sub>5</sub> is a polar amino acid;

X<sub>6</sub> is a polar amino acid;

X<sub>7</sub> is an aromatic or polar amino acid;

X<sub>8</sub> is an aromatic, apolar or polar amino acid;

“-“ is an amide linkage;

5 “=” is a disulfide linkage; and

“≡” is an amide linkage.

21. The method of claim 20 wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently Tyr or Phe;

Z<sub>2</sub> and Z<sub>9</sub> are each Cys;

10 X<sub>3</sub> is absent or Glu;

X<sub>4</sub> is Trp or Leu;

X<sub>5</sub> is Ser;

X<sub>6</sub> is Gln;

X<sub>7</sub> is Tyr or Asn;

15 X<sub>8</sub> is Tyr or Leu;

“-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

22. The method of claim 18 wherein the compound is selected from the group

20 consisting of WP9Q - SEQ ID NO: 13, WP9ELY - SEQ ID NO: 12, WP9Y - SEQ ID NO: 14, and WP9QY - SEQ ID NO: 15.

23. The method of claim 18 wherein the inhibitor has the formula:






B<sub>11</sub> and B<sub>22</sub> are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

- 5           Z<sub>12</sub> is a moiety that is capable of forming a covalent linkage with B<sub>11</sub>, X<sub>13</sub> and Z<sub>21</sub>;  
Z<sub>21</sub> is a moiety that is capable of forming a covalent linkage with B<sub>22</sub>, X<sub>20</sub> and Z<sub>12</sub>;  
X<sub>13</sub> is absent or hydrophobic amino acid;  
X<sub>14</sub> is absent or a hydrophilic amino acid;  
X<sub>15</sub> is a hydrophilic or hydrophobic amino acid;  
10          X<sub>16</sub> is a hydrophilic amino acid;  
X<sub>17</sub> is absent or a hydrophobic amino acid;  
X<sub>18</sub> is a hydrophilic amino acid;  
X<sub>19</sub> is a hydrophilic amino acid;  
X<sub>20</sub> is a hydrophilic amino acid;  
15          “–” is an amide, a substituted amide or an isostere of amide thereof;  
“=” is a covalent linkage; and  
“≡” is a covalent linkage.
24.       The method of claim 23 wherein:
- B<sub>11</sub> and B<sub>22</sub> are each independently a peptide of 1-3 amino acids, at least one of
- 20       which is an aromatic amino acid;

- $Z_{12}$  and  $Z_{21}$  are each independently a Cys-like amino acid;  
 $X_{13}$  is absent or an aromatic amino acid;  
 $X_{14}$  is absent or a polar amino acid;  
 $X_{15}$  is a basic, polar or apolar amino acid;
- 5**  $X_{16}$  is a polar amino acid;  
 $X_{17}$  is absent or an apolar amino acid;  
 $X_{18}$  is an acidic amino acid;  
 $X_{19}$  is a polar amino acid;  
 $X_{20}$  is a basic amino acid;
- 10** “-“ is an amide linkage;  
“=” is a disulfide linkage; and  
“≡” is an amide linkage.
- 25.** The method of claim 24 wherein:
- 15**  $B_{11}$  and  $B_{22}$  are each independently Tyr or Phe;  
 $Z_{12}$  and  $Z_{21}$  are each Cys;  
 $X_{13}$  is absent or Phe;  
 $X_{14}$  is absent or Thr;  
 $X_{15}$  is Ala, Asn or Arg;  
 $X_{16}$  is Ser;
- 20**  $X_{17}$  is absent or Val;  
 $X_{18}$  is Glu;  
 $X_{19}$  is Asn;  
 $X_{20}$  is Arg or His;  
“-“ is an amide linkage;
- 25** “=” is a disulfide linkage; and  
“≡” is an amide linkage.
- 26.** The method of claim 25 wherein the inhibitor is selected from the group consisting of WP5 - SEQ ID NO: 16, WP5N - SEQ ID NO: 17, WP5R - SEQ ID NO: 18, WP5J - SEQ ID NO: 19, WP5JY - SEQ ID NO: 20, WP5JN - SEQ ID NO: 21, WP5JR - SEQ ID

NO: 22, and WP5VR - SEQ ID NO: 23.

27. The method of claim 18 wherein the inhibitor has the formula:



wherein:

- 5         $B_{23}$  and  $B_{33}$  are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
- $Z_{24}$  is a moiety that is capable of forming a covalent linkage with  $B_{23}$ ,  $X_{25}$  and  $Z_{32}$ ;
- $Z_{32}$  is a moiety that is capable of forming a covalent linkage with  $B_{33}$ ,  $X_{31}$  and  $Z_{24}$ ;
- $X_{25}$  is absent or a hydrophilic amino acid;
- 10        $X_{26}$  is a hydrophilic amino acid;
- $X_{27}$  is a hydrophilic amino acid;
- $X_{28}$  is a hydrophobic amino acid;
- $X_{29}$  is a hydrophobic amino acid;
- $X_{30}$  is absent or a hydrophobic amino acid;
- 15        $X_{31}$  is absent or a hydrophobic amino acid;
- “-“ is an amide, a substituted amide or an isostere of amide;
- “=” is a covalent linkage; and
- “≡” is a covalent linkage.

28. The method of claim 27 wherein:

- 20        $B_{23}$  and  $B_{33}$  are each independently a peptide of 1-3 amino acids, at least one of

which is an aromatic amino acid;

Z<sub>24</sub> and Z<sub>32</sub> are each independently a Cys-like amino acid;

X<sub>25</sub> is absent or a basic amino acid;

X<sub>26</sub> is a basic amino acid;

5 X<sub>27</sub> is an acidic amino acid'

X<sub>28</sub> is an apolar amino acid;

X<sub>29</sub> is an apolar amino acid;

X<sub>30</sub> is absent or a polar amino acid;

X<sub>31</sub> is absent or an apolar amino acid;

10 “-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

29. The method of claim 28 wherein:

B<sub>23</sub> and B<sub>33</sub> are each independently Tyr or Phe;

15 Z<sub>24</sub> and Z<sub>32</sub> are each Cys;

X<sub>25</sub> is absent or Arg;

X<sub>26</sub> is Lys;

X<sub>27</sub> is Glu;

X<sub>28</sub> is Leu, Pro or Met;

20 X<sub>29</sub> is Gly;

X<sub>30</sub> is absent or Gln;

X<sub>31</sub> is absent or Val;

“-“ is an amide linkage;

“=” is a disulfide linkage; and

25 “≡” is an amide linkage.

30. The method of claim 29 wherein the inhibitor is selected from the group consisting of WP8L - SEQ ID NO:24.


31. The method of claim 17 wherein the disease characterized by bone loss is selected

from the group consisting of osteoporosis, Paget's disease, metastatic bone disease, rheumatoid arthritis, and periodontal disease.

32. The method of claim 31 wherein the disease characterized by bone loss is osteoporosis.

5 33. A method of inhibiting bone resorption, comprising the step of administering to a patient an amount of an inhibitor effective to inhibit bone resorption.

34. The method of claim 33 wherein said inhibitor has the formula:



(I)

wherein:

10 AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally contain one or more amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

AB<sub>1</sub> is a moiety having a first functional group capable of forming a covalent  
 15 linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB<sub>2</sub> and a third functional group capable of forming a covalent linkage with AA<sub>1</sub> ;

AB<sub>2</sub> is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a  
 20 covalent linkage with AB<sub>1</sub> and a third functional group capable of forming a covalent linkage with AA<sub>2</sub>;

AA<sub>1</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>.

AA<sub>2</sub> is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB<sub>2</sub>.


5            “=” is a covalent linkage; and

“≡” is a covalent linkage.

35. The method of Claim 34 in which the amino acid substitutions are conservative.

36. The method of Claim 35 in which the member of TNF-R superfamily is TNF-R p55.

10 37. The method of Claim 36 wherein the inhibitor has the formula:



wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently a peptide of 1-6 amino acids at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

**15**  $Z_2$  is a moiety that is capable of forming a covalent linkage with  $B_1$ ,  $X_3$  and  $Z_9$ ;

Z<sub>9</sub> is a moiety that is capable of forming a covalent linkage with B<sub>10</sub>, X<sub>8</sub> and Z<sub>7</sub>;

X<sub>3</sub> is absent or a hydrophilic amino acid;

X<sub>4</sub> is a hydrophobic amino acid;

X<sub>5</sub> is a hydrophobic amino acid;

**20** X<sub>6</sub> is a hydrophobic amino acid;

**X<sub>7</sub> is a hydrophobic or hydrophilic amino acid;**

X<sub>8</sub> is a hydrophobic or hydrophilic amino acid;

“-“ is an amide, substituted amide or an isostere of amide thereof;

”=” is a covalent linkage; and

“≡” is a covalent linkage.

5 38. The method of Claim 37, wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently a peptide of 1-2 amino acids, at least one of which is an aromatic amino acid ;

Z<sub>2</sub> and Z<sub>9</sub> are each independently a Cys-like amino acid;

X<sub>3</sub> is absent or an acidic amino acid;

10 X<sub>4</sub> is an aromatic or apolar amino acid;

X<sub>5</sub> is a polar amino acid;

X<sub>6</sub> is a polar amino acid;

X<sub>7</sub> is an aromatic or polar amino acid;

X<sub>8</sub> is an aromatic, apolar or polar amino acid;

15 “-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

39. The method of Claim 38, wherein:

B<sub>1</sub> and B<sub>10</sub> are each independently Tyr or Phe;

20 Z<sub>2</sub> and Z<sub>9</sub> are each Cys;

X<sub>3</sub> is absent or Glu;

X<sub>4</sub> is Trp or Leu;

X<sub>5</sub> is Ser;

X<sub>6</sub> is Gln;

25 X<sub>7</sub> is Tyr or Asn;

X<sub>8</sub> is Tyr or Leu;


“-” is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

40. The method of Claim 39, wherein said inhibitor is selected from the group consisting of WP9Q - SEQ ID NO:13, WP9ELY - SEQ ID NO:12, WP9Y - SEQ ID NO:14, and WP9QY - SEQ ID NO:15.

41. The method of Claim 36, wherein the inhibitor has the formula:



wherein:

B<sub>11</sub> and B<sub>22</sub> are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

$Z_{12}$  is a moiety that is capable of forming a covalent linkage with  $B_{11}$ ,  $X_{13}$  and  $Z_2$ ;

**10**  $Z_{21}$  is a moiety that is capable of forming a covalent linkage with  $B_{22}$ ,  $X_{20}$  and  $Z_{12}$ ;

X<sub>13</sub> is absent or hydrophobic amino acid;

X<sub>4</sub> is absent or hydrophilic amino acid;

X<sub>15</sub> is a hydrophilic or hydrophobic amino acid;

X<sub>16</sub> is a hydrophilic amino acid;

**15** X<sub>17</sub> is absent or a hydrophobic amino acid;

X<sub>18</sub> is a hydrophilic amino acid;

X<sub>19</sub> is a hydrophilic amino acid;

X<sub>20</sub> is a hydrophilic amino acid;

“-” is an amide, a substituted amide or an isostere of amide thereof;

20 “=” is a covalent linkage; and



“≡” is a covalent linkage.

42. The method of Claim 41, wherein:

B<sub>11</sub> and B<sub>22</sub> are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic amino acid;

5 Z<sub>12</sub> and Z<sub>21</sub> are each independently a Cys-like amino acid;

X<sub>13</sub> is absent or an aromatic amino acid;

X<sub>14</sub> is absent or a polar amino acid;

X<sub>15</sub> is a basic, polar or apolar amino acid;

X<sub>16</sub> is a polar amino acid;

10 X<sub>17</sub> is absent or an apolar amino acid;

X<sub>18</sub> is an acidic amino acid;

X<sub>19</sub> is a polar amino acid;

X<sub>20</sub> is a basic amino acid;

“-“ is an amide linkage;

15 “=” is a disulfide linkage; and

“≡” is an amide linkage.

43. The method of Claim 42, wherein:

B<sub>11</sub> and B<sub>22</sub> are each independently Tyr or Phe;

Z<sub>12</sub> and Z<sub>21</sub> are each Cys;

20 X<sub>13</sub> is absent or Phe;

X<sub>14</sub> is absent or Thr;

X<sub>15</sub> is Ala, Asn or Arg;

X<sub>16</sub> is Ser;

X<sub>17</sub> is absent or Val;

25 X<sub>18</sub> is Glu;

X<sub>19</sub> is Asn;

X<sub>20</sub> is Arg or His;


“-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

44. The method of Claim 43, wherein said inhibitor is selected from the group consisting of WP5 - SEQ ID NO:16, WP5N - SEQ ID NO:17, WP5R - SEQ ID NO:18, WP5J - SEQ ID NO:19, WP5JY - SEQ ID NO:20, WP5JN - SEQ ID NO:21, WP5JR -  
5 SEQ ID NO:22, and WP5VR - SEQ ID NO:23.

45. The method of Claim 36, wherein the inhibitor has the formula:



wherein:

- $B_{23}$  and  $B_{33}$  are each independently a peptide of 1-6 amino acids, at least one of  
10 which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;  
 $Z_{24}$  is a moiety that is capable of forming a covalent linkage with  $B_{23}$ ,  $X_{25}$  and  $Z_{32}$ ;  
 $Z_{32}$  is a moiety that is capable of forming a covalent linkage with  $B_{33}$ ,  $X_{31}$  and  $Z_{24}$ ;  
 $X_{25}$  is absent or a hydrophilic amino acid;  
 $X_{26}$  is a hydrophilic amino acid;  
15  $X_{27}$  is a hydrophilic amino acid;  
 $X_{28}$  is a hydrophilic amino acid;  
 $X_{29}$  is a hydrophilic amino acid;  
 $X_{30}$  is absent or a hydrophilic amino acid;  
 $X_{31}$  is absent or a hydrophilic amino acid;  
20 “-” is an amide, a substituted amide or an isostere of amide;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

46. The method of Claim 45, wherein:

B<sub>23</sub> and B<sub>33</sub> are each independently a peptide of 1-3 amino acids, at least one of

5 which is an aromatic amino acid;

Z<sub>24</sub> and Z<sub>32</sub> are each independently a Cys-like amino acid;

X<sub>25</sub> is absent or a basic amino acid;

X<sub>26</sub> is a basic amino acid;

X<sub>27</sub> is an acidic amino acid;

10 X<sub>28</sub> is an apolar amino acid;

X<sub>29</sub> is an apolar amino acid;

X<sub>30</sub> is absent or a polar amino acid;

X<sub>31</sub> is absent or an apolar amino acid;

“-“ is an amide linkage’

15 “=” is a disulfide linkage; and

“≡” is an amide linkage.

47. The method of Claim 46, wherein:

B<sub>23</sub> and B<sub>33</sub> are each independently Tyr or Phe;

Z<sub>24</sub> and Z<sub>32</sub> are each Cys;

20 X<sub>25</sub> is absent or Arg;

X<sub>26</sub> is Lys;

X<sub>27</sub> is Glu;

X<sub>28</sub> is leu, Pro or Met;

X<sub>29</sub> is Gly;

25 X<sub>30</sub> is absent or Gln;

X<sub>31</sub> is absent or Val;

“-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

48. The method of Claim 47, wherein said inhibitor is selected from the group consisting of WP8L - SEQ ID NO:24, WP8JP - SEQ ID NO:25, WP8J - SEQ ID NO:26, and WP8JF - SEQ ID NO:27.

**ABSTRACT**

Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. The present invention also provides peptides and peptide analogues designed  
5 from a binding loop of a member of the tumor necrosis factor receptor (TNF-R) superfamily. According to the methods, an amount of an inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of  
10 an inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
219




Figure 1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In Re Application of:

Mark I. Greene, Ramachandran Murali, Kazuhiro  
Aoki, William Carle Horne and Roland Baron

**Group Art Unit:** Not yet  
assigned

**For:** METHODS OF INHIBITING  
OSTEOCLASTOGENESIS

**Examiner:** Not yet assigned

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a

☒ Utility Patent      ☐ Design Patent

is sought on the invention, whose title appears above, the specification of which:

☒ is attached hereto.  
☐ was filed on \_\_\_\_\_ as Serial No. \_\_\_\_\_  
☐ said application having been amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a-d) of any **foreign application(s)** for patent or inventor's certificate listed below and have also identified below

any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Priority Claimed (If X'd)	Country	Serial Number	Date Filed
<input type="checkbox"/>	_____	_____	_____
<input type="checkbox"/>	_____	_____	_____
<input type="checkbox"/>	_____	_____	_____
<input type="checkbox"/>	_____	_____	_____

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Date Filed	Patented/Pending/Abandoned
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional



application(s) listed below:

### Serial Number

**Date Filed**

60/146,090

July 28, 1999

I hereby appoint the following persons of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103 as attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Mark DeLuca

Reg. No. 33,229

Gwilym J. O. Attwell

Reg. No. 45,449

Address all telephone calls and correspondence to:

**Gwilym J. O. Attwell**  
**WOODCOCK WASHBURN KURTZ**  
**MACKIEWICZ & NORRIS LLP**  
 One Liberty Place - 46th Floor  
 Philadelphia PA 19103  
 Telephone No.: **(215) 568-3100**  
 Facsimile No.: **(215) 568-3439**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

<b>Name:</b> Mark I. Greene	
<b>Mailing Address:</b> 300 Righters Mill Road Penn Valley Pennsylvania 19072	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Penn Valley, Pennsylvania	<b>Citizenship:</b> <u>United States</u>

<b>Name:</b> Ramachandran Murali	
<b>Mailing Address:</b> 41-6 Revere Road Drexel Hill, Pennsylvania 19026	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Drexel Hill, Pennsylvania 19026	<b>Citizenship:</b> <u>India</u> _____

<b>Name:</b> Kazuhiro Aoki	
<b>Mailing Address:</b> 3-10-10-807 Izumi-cho Narashino-shi Chiba 275-0006 JAPAN	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Chiba 275-0006 JAPAN	<b>Citizenship:</b> <u>Japanese</u>

<b>Name:</b> William Carle Horne	
<b>Mailing Address:</b> 246 Pleasant Point Road Branford, CT 06405	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Branford, CT	<b>Citizenship:</b> <u>United States</u>

<b>Name:</b> Roland Baron	
<b>Mailing Address:</b> 9 Little Harbor Road Guilford, CT 06437	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Guilford, CT 06437	<b>Citizenship:</b> <u>United States</u>

<b>Name:</b>	
<b>Mailing Address:</b>	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b>	<b>Citizenship:</b> _____

2025 RELEASED

# SEQUENCE LISTING

<110> Greene, Mark  
Murali, Ramachandran  
Aoki, Kazuhiro  
Baron, Roland

<120> Methods of Inhibiting Osteoclastogenesis

<130> UPN3832

<140>

<141>

<150> 60/146,090

<151> 1999-07-28

<160> 29

<170> PatentIn Ver. 2.1

<210> 1

<211> 74

<212> PRT

<213> Homo sapiens

<400> 1

Asp	Cys	Arg	Glu	Cys	Glu	Ser	Gly	Ser	Phe	Thr	Ala	Ser	Glu	Asn	His
1				5					10					15	

Leu	Arg	His	Cys	Leu	Ser	Cys	Ser	Lys	Cys	Arg	Lys	Glu	Met	Gly	Gln
			20					25					30		

Val	Glu	Ile	Ser	Ser	Cys	Thr	Val	Asp	Arg	Asp	Thr	Val	Cys	Gly	Cys
		35					40					45			

Arg	Lys	Asn	Gln	Tyr	Arg	His	Tyr	Trp	Ser	Glu	Asn	Leu	Phe	Gln	Cys
	50					55					60				

Phe	Asn	Cys	Ser	Leu	Cys	Leu	Asn	Gly	Thr
65					70				

<210> 2

<211> 77

<212> PRT

<213> Homo sapiens

<400> 2

Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp  
1 5 10 15

Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val  
20 25 30

Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys Arg  
35 40 45

Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg Leu Cys  
50 55 60

Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala  
65 70 75

<210> 3

<211> 77

<212> PRT

<213> Homo sapiens

<400> 3

Val Cys Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr  
1 5 10 15

Leu Thr Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu  
20 25 30

Glu Glu Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys  
35 40 45

Gln Pro Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys  
50 55 60

Glu Leu Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu  
65 70 75

<210> 4

<211> 76

<212> PRT

<213> Homo sapiens

<400> 4

Cys Glu Pro Cys Leu Asp Ser Val Thr Phe Ser Asp Val Val Ser Ala  
1 5 10 15

Thr Glu Pro Cys Lys Pro Cys Thr Glu Cys Val Gly Leu Gln Ser Met  
20 25 30

Ser Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr  
35 40 45

Gly Tyr Tyr Gln Asp Glu Thr Thr Gly Arg Cys Glu Ala Cys Arg Val  
50 55 60

Cys Glu Ala Gly Ser Gly Leu Val Phe Ser Cys Gln  
65 70 75

<210> 5  
<211> 53  
<212> PRT  
<213> Homo sapiens

<400> 5  
Gln Cys Asp Pro Cys Ile Pro Gly Val Ser Phe Ser Pro Asp His His  
1 5 10 15

Thr Arg Pro His Cys Glu Ser Cys Arg His Cys Asn Ser Gly Leu Leu  
20 25 30

Val Arg Asn Cys Thr Ile Thr Ala Asn Ala Glu Cys Ala Cys Arg Asn  
35 40 45

Gly Trp Gln Cys Arg  
50

<210> 6  
<211> 74  
<212> PRT  
<213> Homo sapiens

<400> 6  
Cys Arg Lys Gln Cys Glu Pro Asp Tyr Tyr Leu Asp Glu Ala Asp Arg  
1 5 10 15

Cys Thr Ala Cys Val Thr Cys Ser Arg Asp Asp Leu Val Glu Lys Thr  
20 25 30

Pro Cys Ala Trp Asn Ser Ser Arg Val Cys Glu Cys Arg Pro Gly Met  
35 40 45

Phe Cys Ser Thr Ser Ala Val Asn Ser Cys Ala Arg Cys Phe Phe His

50

55

60

Ser Val Cys Pro Ala Gly Met Ile Val Lys  
65 70

&lt;210&gt; 7

&lt;211&gt; 74

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

Cys Arg Lys Gln Cys Glu Pro Asp Tyr Tyr Leu Asp Glu Ala Gly Arg  
1 5 10 15

Cys Thr Ala Cys Val Ser Cys Ser Arg Asp Asp Leu Val Glu Lys Thr  
20 25 30

Pro Cys Ala Trp Asn Ser Ser Arg Thr Cys Glu Cys Arg Pro Gly Met  
35 40 45

Ile Cys Ala Thr Ser Ala Thr Asn Ser Cys Ala Arg Cys Val Pro Tyr  
50 55 60

Pro Ile Cys Ala Ala Glu Thr Val Thr Lys  
65 70

&lt;210&gt; 8

&lt;211&gt; 75

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

Glu Cys Leu Pro Cys Gly Glu Ser Glu Phe Leu Asp Thr Trp Asn Arg  
1 5 10 15

Glu Thr His Cys His Gln His Lys Tyr Cys Asp Pro Asn Leu Gly Leu  
20 25 30

Arg Val Gln Gln Lys Gly Thr Ser Glu Thr Asp Thr Ile Cys Thr Cys  
35 40 45

Glu Glu Gly Trp His Cys Thr Ser Glu Ala Cys Glu Ser Cys Val Leu  
50 55 60

His Arg Ser Cys Ser Pro Gly Phe Gly Val Lys  
65 70 75

<210> 9  
 <211> 34  
 <212> PRT  
 <213> Homo sapiens

<400> 9  
 Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His  
 1 5 10 15

Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly  
 20 25 30

Leu Glu

<210> 10  
 <211> 58  
 <212> PRT  
 <213> Homo sapiens

<400> 10  
 Cys Arg Pro Cys Gly Pro Gly Phe Tyr Asn Asp Val Val Ser Ser Lys  
 1 5 10 15

Pro Cys Lys Pro Cys Thr Trp Cys Asn Leu Arg Ser Gly Ser Glu Arg  
 20 25 30

Lys Gln Leu Cys Thr Ala Thr Gln Asp Thr Asp Thr Val Cys Arg Cys  
 35 40 45

Arg Ala Gly Thr Gln Pro Leu Asp Ser Tyr  
 50 55

<210> 11  
 <211> 69  
 <212> PRT  
 <213> Homo sapiens

<400> 11  
 Cys Ser Pro Cys Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg  
 1 5 10 15

Thr Cys Asp Ile Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys  
 20 25 30



Glu Cys Ser Ser Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe  
35 40 45

His Cys Leu Gly Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln  
50 55 60

Gly Gln Glu Leu Thr  
65

<210> 12  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 12  
Tyr Cys Glu Leu Ser Gln Tyr Leu Cys Tyr  
1 5 10

<210> 13  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 13  
Tyr Cys Trp Ser Gln Asn Leu Cys Tyr  
1 5

<210> 14  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 14  
Tyr Cys Trp Ser Gln Asn Tyr Cys Tyr  
1 5

<210> 15  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 15  
Tyr Cys Trp Ser Gln Tyr Leu Cys Tyr  
1 5

<210> 16  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 16  
Tyr Cys Phe Thr Ala Ser Glu Asn His Cys Tyr  
1 5 10

<210> 17  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 17  
Tyr Cys Phe Thr Asn Ser Glu Asn His Cys Tyr  
1 5 10

<210> 18  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 18

Tyr Cys Phe Thr Arg Ser Glu Asn His Cys Tyr

1 5 10

<210> 19

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 19

Phe Cys Ala Ser Glu Asn His Cys Tyr

1 5

<210> 20

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 20

Tyr Cys Ala Ser Glu Asn His Cys Tyr

1 5

<210> 21

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 21

Phe Cys Asn Ser Glu Asn His Cys Tyr

1 5

<210> 22

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 22

Phe Cys Asn Ser Glu Asn Arg Cys Tyr

1

5

<210> 23

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 23

Phe Cys Asn Ser Val Glu Asn Arg Cys Tyr

1

5

10

<210> 24

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 24

Tyr Cys Arg Lys Glu Leu Gly Gln Val Cys Tyr

1

5

10

<210> 25

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 25

Tyr Cys Lys Glu Pro Gly Gln Cys Tyr

1

5

<210> 26  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 26  
Tyr Cys Arg Lys Glu Met Gly Cys Tyr  
1 5

<210> 27  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 27  
Phe Cys Arg Lys Glu Met Gly Cys Tyr  
1 5

<210> 28  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 28  
Tyr Cys Ser Gln Ser Val Ser Asn Asp Cys Phe  
1 5 10

<210> 29  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Novel Sequence

<400> 29

Phe Cys Val Ser Asn Asp Arg Cys Tyr

1

5